Document:

Development and Supply Agreement - Luna Innovations Incorporated

 Exhibit 10.48 
 CONFIDENTIAL TREATMENT REQUESTED 
 DEVELOPMENT AND
SUPPLY AGREEMENT 
 This Development and Supply Agreement (“Agreement”) is dated and made effective as of
the Effective Date (as defined below) by and between Luna Innovations Incorporated, a Delaware corporation, together with Luna Technologies, Inc., a Delaware corporation (acting jointly and severally, individually and collectively,
“Luna”), and Hansen Medical, Inc., a Delaware corporation (“Hansen”). Luna and Hansen are referred to herein each individually as a “Party” and collectively as the “Parties”.

 RECITALS 
 WHEREAS, Luna and Hansen are parties to the case Hansen Medical Inc. v. Luna Innovations Inc., no. 07-088551, in the Superior Court of the State of California, County of Santa Clara relating
to certain disputes arising out of those certain Terms and Conditions of Sale and Service executed by Hansen on September 27, 2006 and Luna on September 28, 2006 and that certain Mutual Nondisclosure Agreement between Hansen and Luna dated
April 1, 2006 (the “Litigation”); 
 WHEREAS, Luna and Hansen wish to settle the Litigation in the
context of the First Amended Joint Plan of Reorganization of Luna Innovations Incorporated, et al. under Chapter 11 of the Bankruptcy Code (as may be amended, “Amended Plan”) in Luna’s Chapter 11 Case No. 09-71811
(“Chapter 11 Case”) pending in the U.S. Bankruptcy Court for the Western District of Virginia (“Bankruptcy Court”) which Amended Plan was approved by the Bankruptcy Court’s Order Confirming First Amended Joint
Plan of Reorganization of Luna Innovations Incorporated, et al. (“Confirmation Order”). This Agreement is one of the “Hansen Settlement Documents” (as defined in the Settlement Agreement) referenced and incorporated in the
Amended Plan and Confirmation Order (“Settlement Documents”); 
 WHEREAS, in connection with the
settlement of the Litigation through the Amended Plan, Luna and Hansen are entering into that certain License Agreement Between Hansen and Luna dated of even date herewith (the “License Agreement”), and Luna and Intuitive are
entering into that certain License Agreement between Intuitive and Luna dated of even date herewith (the “Intuitive-Luna License”) in each case regarding the grant of certain licenses to fiber optic shape sensing or localization
technologies; and 
 WHEREAS, also in connection with the settlement of the Litigation through the Amended Plan, Luna and
Hansen desire that Luna develop for Hansen a localization and shape sensing solution for Hansen’s robotic system, and to manufacture and supply such system for Hansen, all in accordance with the terms and conditions hereof. 
 NOW, THEREFORE, in view of the mutual covenants, representations, warranties and other terms and conditions contained herein
and for other valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereto agree as follows: 
 AGREEMENT 
 1. Definitions. The following initially capitalized words shall have the following meanings
(and derivative forms shall be interpreted accordingly), and the terms “include,” “includes,” “including” and derivative forms of them shall be deemed followed by the phrase “without limitation” regardless of
whether such phrase appears there (and with no implication being drawn from its inconsistent inclusion or non-inclusion): 
 1.1 “Additional Performance Period” has the meaning given to such term in Section 4.1.3. 

 1.2 “Affiliates” means any corporation or other entity that is
directly or indirectly controlling, controlled by or under common control with a Party. For purposes of this definition, “control” of an entity means the direct or indirect ownership of securities representing fifty percent (50%) or
more of the total voting power entitled to vote in elections of such entity’s board of directors or other governing authority, or equivalent interests conferring the power to direct or cause the direction of the governance or policies of such
entity. 
 1.3 “Amended Plan” has the meaning given to such term in the recitals. 
 1.4 “Applicable Laws” means all applicable laws, rules and regulations. 
 1.5 “Bankruptcy Court” has the meaning given to such term in the recitals. 
 1.6 “Budget Cap” has the meaning given to such term in Section 4.1.3. 
 1.7 “Chapter 11 Case” has the meaning given to such term in the recitals. 
 1.8 “Commercial Supply Agreement” has the meaning given to such term in Section 3.3.1. 
 1.9 “Commercial Transfer Price” has the meaning given to such term in Section 3.3.2. 
 1.10 “Confidential Information” has the meaning given to such term in Section 7.1. 
 1.11 “Confirmation Order” has the meaning given to such term in the recitals. 
 1.12 “[****] Fees” has the meaning given to such term in Section 4.1.1. 
 1.13 “[****] Milestones” means the development milestones and corresponding timelines set forth on Exhibit A, as may
be amended from time to time in accordance with Section 2.2. 
 1.14 “Development Plan” means the
development plan described in Section 2. 
 1.15 “Development Program” means the efforts and
activities relating to development of Luna Products to be conducted under this Agreement. 
 1.16 “[****]
Price” has the meaning given to such term in Section 3.2. 
 1.17 “Discloser” has the
meaning given to such term in Section 7.1. 
 1.18 “Effective Date” means the Effective Date of the
Amended Plan after entry of the Confirmation Order by the Bankruptcy Court, which the Parties hereby confirm to be January 12, 2010. 
 1.19 “End Product” means any Product developed, marketed, manufactured or sold by or for Hansen or its Affiliates incorporating or utilizing any Luna Product. 
  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
 2 

 1.20 “[****] Field” has the meaning given to such term in the
License Agreement. 
 1.21 “[****] Product” has the meaning given to such term in Section 3.8.1.

 1.22 “Fiber Optic Shape Sensing/Localization Technology” has the meaning given to such term in the
License Agreement. 
 1.23 “Hansen Indemnitees” has the meaning given to such term in Section 8.2.

 1.24 “Hansen Licensed IP” has the meaning given to such term in the License Agreement. 
 1.25 “Holdback Amount” has the meaning given to such term in Section 4.1.1. 
 1.26 “Indemnifying Party” has the meaning given to such term in Section 8.3. 
 1.27 “Intellectual Property Rights” means any and all of the following in any jurisdiction throughout the world (and
any rights or interests therein): (a) patents, patent applications and patent and invention disclosures, together with all issuances, continuations, continuations-in-part, divisions, revisions, supplementary protection certificates, extensions
and re-examinations thereof, and any other United States or foreign patent rights entitled to the same priority claim (in whole or in part) as any of the foregoing; (b) confidential or proprietary information, know-how and trade secrets;
(c) copyrights and all applications, registrations, and renewals in connection with the foregoing; (d) trademarks, service marks, trade names, trade dress and all registrations to and applications for registration of any of the foregoing;
and (e) any and all other intellectual or industrial property or proprietary rights. 
 1.28
“Interrogator” has the meaning given to such term in Section 1.36. 
 1.29 “Joint
Patents” has the meaning given to such term in Section 5.2.2. 
 1.30 “License Agreement”
has the meaning given to such term in the recitals. 
 1.31 “Licensed IP” has the meaning given to such
term in the License Agreement. 
 1.32 “Licensed Patent” has the meaning given to such term in the
License Agreement. 
 1.33 “Litigation” has the meaning given to such term in the recitals. 

1.34 “Losses” has the meaning given to such term in Section 8.1. 
 1.35 “Luna Indemnitees” has the meaning given to such term in Section 8.1. 
 1.36 “Luna Product” means [****]. 
 1.37 “[****] Field” has the meaning given to such term in the License Agreement. 
 1.38 “New Inventions” has the meaning given to such term in Section 5.2. 
  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
 3 

 1.39 “[****] Field” has the meaning given to such term in the
License Agreement. 
 1.40 “[****] Product” has the meaning given to such term in Section 3.8.1.

 1.41 “[****] Field” has the meaning given to such term in the License Agreement. 
 1.42 “Product” means any device, instrument, diagnostic, therapeutic, product, system and application and any
related service and/or process. 
 1.43 “Project Manager” has the meaning given to such term in
Section 2.3. 
 1.44 “Promissory Note” means that certain Secured Promissory Note entered into
between the Parties as one of the Settlement Documents. 
 1.45 “Recipient” has the meaning given to
such term in Section 7.1. 
 1.46 “Section 365(n) Contract” has the meaning given to such term in
Section 10.6. 
 1.47 “Sensor” has the meaning given to such term in Section 1.36. 

1.48 “Settlement Agreement” means that certain Confidential Settlement Agreement and Mutual Release entered into
by the Parties concurrently herewith. 
 1.49 “Settlement Documents” has the meaning given to such term
in the recitals. 
 1.50 “Specifications” means the technical and functional specifications for the
applicable Luna Product (including applicable tests to confirm compliance therewith) set forth in the Development Plan and as otherwise provided for in Section 2.2. 
 1.51 “Subsidiaries” has the meaning given to such term in the License Agreement. 
 1.52 “Support Memorandum” has the meaning given to such term in Section 2.6. 
 1.53 “Technology” means any technical information, know-how, processes, procedures, methods, formulae, protocols, techniques, software, computer code (including both object and
source code), documentation, works of authorship, data, designations, designs, devices, prototypes, substances, components, inventions (whether or not patentable), mask works, ideas, trade secrets and other information or materials, in tangible or
intangible form. 
 1.54 “Third Party Claim” has the meaning given to such term in Section 8.1.

 1.55 “Third Party Technology” means any Technology (together with all Intellectual Property Rights
therein or thereunder) owned or controlled by a third party that is included by or for Luna in or with any Luna Product or provided to Hansen by Luna in connection with the Development Program or is otherwise necessary for the manufacture, use or
sale of any Luna Product. 
 1.56 “[****] Field” has the meaning given to such term in the License
Agreement. 
  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
 4 

 2. Development 
 2.1 Development Program. Luna shall use its commercially reasonable best efforts to develop for Hansen a [****] for Hansen’s
system in accordance with the Development Plan and the Development Milestones. As a part of such commercially reasonable best efforts, Luna shall provide reasonably adequate and appropriately-skilled staffing for Luna’s development work for
Hansen hereunder, which in any event shall include Luna devoting to the Development Program the services of the key personnel designated in the Development Plan at the minimum percentage amounts of their total work time set forth therein (as
measured over each calendar quarterly period during the Development Program by reference to direct labor time records). Furthermore, Luna shall use its commercially reasonable best efforts to perform the activities, and develop the Technology, as
and when described in the Development Plan and the Amended Plan, and Luna shall use its commercially reasonable best efforts to achieve each Development Milestone within the applicable timelines and/or by the applicable deadlines for such
Development Milestone set forth on Exhibit A. Without limiting the foregoing, (i) the Parties acknowledge that Luna already has certain ongoing development obligations to Intuitive Surgical, Inc., certain internal product development efforts,
and under certain government contracts as of the Effective Date but Luna shall give the Development Program for Hansen at least equal priority to such other obligations (and balance its development work for Hansen and such other parties
accordingly), (ii) Luna shall give the Development Program for Hansen at least equal priority to any other development project or similar activities (whether for itself, its Affiliates or for third parties) not described in (i) above,
including pursuant to an agreement entered into after the Effective Date, and (iii) Luna may need to hire additional highly qualified employees, possibly because of the loss of employees, and the ability and timing of hiring such employees
cannot be guaranteed. The Parties acknowledge that technical and scientific issues and realities may make either or both the Development Plan or the Development Milestones impractical or infeasible. Hansen shall compensate Luna for such development
and related activities solely as provided for in Article 4 below. 
 2.2 Development Plan. Luna’s development work
hereunder shall be conducted pursuant to a written development plan (the “Development Plan”). The Development Plan shall include a detailed workplan (including incorporation of, or reference to, the Development Milestones) and
budget covering the Development Program activities to be conducted under this Agreement. The initial Development Plan is attached hereto as Exhibit B (and the Development Milestones are attached as Exhibit A). The Parties may from time to time
modify the Development Plan (including the Development Milestones), as mutually agreed. Furthermore, the Development Plan and Development Milestones may be modified in accordance with the process described below in Sections 2.2.1 through 2.2.4. The
Specifications shall be part of the Development Plan, or, to the extent not so specified in the Development Plan, independently established in writing in a document executed by both Parties, and any changes thereto (and/or any initial determination
thereof) shall be done in accordance with this Section 2.2. The Development Plan (including the Specifications) and Development Milestones may not be modified other than in accordance with this Section 2.2. 
 2.2.1 If Hansen wishes to request changes to the Development Plan (including the Specifications) and/or the Development Milestones,
Hansen shall notify Luna and propose a draft of the modified Development Plan and/or modified Development Milestones for review by Luna. Luna shall provide reasonable consultation and assistance to Hansen in Hansen’s efforts to modify the
Development Plan and the Development Milestones. Luna shall provide Hansen with any comments on the proposed modifications and a reasonable estimate of changes to the budget, if any, necessitated by the modifications within [****] days of
Hansen’s request. If Luna has concerns with respect to the timelines for any substantial new Development Milestones or substantial modifications to existing Development 
  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
 5 

 
Milestones (whether on their own or as a result of modifications to the Development Plan) proposed by Hansen, Luna shall provide Hansen with a reasonably detailed explanation for Luna’s
concerns and a proposal with reasonably estimated timelines for such Development Milestones. Hansen shall consider Luna’s concerns and proposed budget and timelines in good faith in finalizing the modified Development Plan and/or Development
Milestones. No sooner than [****] days after first providing to Luna Hansen’s proposed modifications to the Development Plan and/or the Development Milestones in accordance with the foregoing, Hansen may formally propose a final modified
Development Plan and/or modified Development Milestones by providing a copy thereof to Luna. Luna shall thereupon have [****] days to approve such modified Development Plan and/or Development Milestones, such approval not to be unreasonably
withheld. 
 2.2.2 Upon any such approval by Luna under Section 2.2.1, such modified Development Plan (including
modified Specifications if applicable) and/or modified Development Milestones shall become the Development Plan and/or Development Milestones (as applicable) hereunder and shall replace the previous Development Plan and/or previous Development
Milestones (as applicable), except to the extent the modified version expressly incorporates such previous Development Plan and/or Development Milestones or otherwise expressly provides for existing portions thereof to remain in effect. 

2.2.3 If Luna does not approve the proposed modifications under Section 2.2.1 within the [****] day period specified above,
the Parties shall discuss in good faith for a period of at least [****] days to reach mutual agreement on the proposed modifications. Otherwise, absent such agreement within such [****] day period, Hansen shall have the right at any time after such
[****] day period to submit its proposed modifications (including any determination of Specifications, if applicable) to binding dispute resolution under Section 2.6 hereunder, and (to the extent not otherwise resolved prior to completion of
any arbitration thereunder) the arbitrator under any arbitration pursuant to Section 2.6 shall be empowered hereunder to determine whether or not Luna’s failure to approve is reasonable (and therefore if Hansen’s proposed
modifications shall become effective hereunder) and/or determine an alternative form of the modifications that is fair to Luna in light of Luna’s objections to Hansen’s formally proposed modifications but which also most nearly achieves
Hansen’s goals and objectives of such proposed modifications. 
 2.2.4 If Luna wishes to request changes to the
Development Plan (including the Specifications) and/or Development Milestones, it shall notify Hansen thereof and inform Hansen of the proposed modifications. Luna and Hansen shall thereupon discuss such modifications. No sooner than [****] days
after first providing to Hansen Luna’s proposed modifications to the Development Plan and/or the Development Milestones in accordance with the foregoing, Luna may formally propose a final modified Development Plan and/or modified Development
Milestones by providing a copy thereof to Hansen. Hansen shall thereupon have [****] days to approve such modified Development Plan and/or Development Milestones, such approval not to be unreasonably withheld so long as such proposed modifications
are consistent with the reasonable development of a commercially viable End Product and do not significantly increase the budget. If Hansen approves such modification, such modified Development Plan (including modified Specifications if applicable)
and/or modified Development Milestones shall become the Development Plan and/or Development Milestones (as applicable) hereunder and shall replace the previous Development Plan and/or previous Development Milestones (as applicable), except to the
extent the modified version expressly incorporates such previous Development Plan and/or Development Milestones or otherwise expressly provides for existing portions thereof to remain in effect. If Hansen does not approve the proposed modifications
within the [****] day period specific above, Section 2.2.3 shall apply with respect thereto, with the Parties in such section reversed. 
  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
 6 

 2.3 Project Managers. Each Party shall appoint a principal point of contact to be its
project manager (each, a “Project Manager”) who shall coordinate and act as liaison with the other Party with respect to Development Program activities under this Agreement. The initial Project Managers for each Party shall be
[****] for Hansen and [****] for Luna. A Party may replace its Project Manager by written notice to the other Party. The Project Managers, in and of themselves, shall not have any decision-making authority and shall have no power to amend or waive
compliance with this Agreement or the Development Plan or create any estoppel or defense. Each Party’s respective Project Managers shall meet or confer at mutually agreeable times (but at least [****]) to discuss the status of the Development
Program. Luna’s Project Manager shall have no direct role in or with respect to any products or services provided by Luna to Intuitive Surgical, Inc., a Delaware corporation. 
 2.4 Reports; Source Code Escrow. Luna shall keep Hansen informed of its progress with respect to its Development Program activities
under this Agreement at the junctures set forth in the Development Plan and as follows. Luna shall provide Hansen with written development reports upon Hansen’s reasonable request (made no more frequently than once per month) and also to the
extent provided for in the Development Plan or Development Milestones, but in any event no less frequently than within [****] days after the end of each calendar month, which reports will include a meaningful summary of progress against the
Development Plan and activities accomplished by Luna in relation thereto through the end of the applicable month, including a summary of Technology generated or developed under the Development Program since the date of the last report, significant
results, adverse event reports, information and data generated, manufacturing developments, significant challenges anticipated and updates regarding significant intellectual property matters. Upon Hansen’s reasonable request at reasonable
intervals, Luna will provide Hansen with a copy of tangible and intangible embodiments of Technology generated or developed under the Development Program, including prototypes and models, documents (including specifications and diagrams) and
software object code (and, to the extent provided below, software source code), at such times as are reasonable under the circumstances (e.g., after completion of a new version thereof or when a reasonable stopping point in development is reached
with respect thereto or a pause in development thereof is warranted); provided, however, that, to the extent the cost of such embodiments, prototypes and models is not included in the Development Plan or is not otherwise covered by
Section 3.2, Hansen shall reimburse Luna for the cost (calculated at the same rate as the rate described in Section 4.1) thereof (without any effect on any Budget Cap in the case of such reimbursement). Luna shall make its personnel
working on the Development Program reasonably available to Hansen for periodic consultations, by phone or in person (which shall be part of the services provided pursuant to Section 2.1 and compensated for under Section 4.1 (including
subject to the budget provisions therein)), as provided for in the Development Plan and Development Milestones, and otherwise as reasonably requested by Hansen. With respect to source code, the following shall apply: 
 2.4.1 Luna shall cooperate with Hansen to provide any software source code with respect to the Luna Product to the extent required
by any Applicable Laws, including regulatory requirements of the FDA and other applicable governmental entities in respect of the Luna Product and/or the End Product within such time periods as reasonably required for compliance. Luna shall provide
to Hansen the portions of software source code with respect to the Luna Product to the extent set forth as a deliverable in the Development Plan (including in the Development Milestones) in accordance with the schedule therefore in the Development
Plan (including in the Development Milestones). 
 2.4.2 Following the Effective Date, Luna shall deposit in escrow all
source code for software necessary to operate the Luna Product (including source code for software within the Interrogator, as may exist as of the Effective Date and as updated), as imaged on a hard drive with all of the 
  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
 7 

 
files and utilities necessary to compile or synthesize the source code, together with any documentation, libraries, tools, utilities and other related materials reasonably necessary for the
installation, testing, deployment, operation, modification or use of such software source code (collectively, “Luna Product Deposit Materials”) with [****] (or, if [****] is not reasonably available, with another reputable software
escrow company to be mutually agreed by the Parties). Luna shall periodically update such Luna Product Deposit Materials with the latest versions thereof, but no less frequently than once each [****]. The Luna Product Deposit Materials shall be
released to Hansen in the event any of the following occurs (but not in any other case): (i) refusal of Luna to perform continued development, maintenance, upgrading and support of the software within the Luna Product Deposit Materials under
Luna’s standard rates and under other reasonable and customary terms (it being understood that Luna has no obligation to do so hereunder outside of the Development Program) or failure of Luna to provide such services after agreeing to do so
(following notice and an opportunity to cure such failure within [****] days), and (ii) the bankruptcy, liquidation or insolvency of Luna or an assignment for the benefit of creditors by Luna. All fees and expenses payable to [****] (or such
other escrow company, if any) for the establishment and maintenance of such escrow arrangement shall be borne and paid by Hansen. 
 2.4.3 Following the Effective Date, Luna shall deposit in escrow all source code for software included within the Licensed IP, as imaged on a hard drive with all of the files and utilities necessary to compile or synthesize the
source code, together with any documentation, libraries, tools, utilities and other related materials reasonably necessary for the installation, testing, deployment, operation, modification or use of such software source code (collectively,
“Technology Deposit Materials”) with [****] (or, if [****] is not reasonably available, with another reputable software escrow company to be mutually agreed by the Parties). Luna shall periodically update such Technology Deposit
Materials with the latest versions thereof at least annually. The Technology Deposit Materials shall be released to Hansen in the event any of the following occurs (but not in any other case): (i) a default occurs under the Promissory Note
which default is not cured within any time allotted for such cure under such Promissory Note, and (ii) the bankruptcy, liquidation or insolvency of Luna or an assignment for the benefit of creditors by Luna. The escrow arrangement for the
Technology Deposit Materials shall terminate upon payment in full of the Promissory Note (at which point all such Technology Deposit Materials, if not already released to Hansen, shall be returned to Luna). All fees and expenses payable to [****]
(or such other escrow company, if any) for the establishment and maintenance of such escrow arrangement shall be borne and paid by Hansen, except that Luna shall pay any annual escrow maintenance fees of [****] (or such other escrow company).

 2.4.4 Within [****] days following the Effective Date, the Parties shall negotiate and enter into an escrow agreement
between the Parties and [****] (or such other escrow company, if any) to establish the escrow arrangement described above under the terms and conditions described above (and other reasonable and customary terms and conditions). Luna shall make the
initial deposit of the materials described above into escrow within [****] days after such agreement is entered into. In the event the Parties fail to execute such escrow agreement within [****] days after the Effective Date, either Party may refer
the matter to dispute resolution under Section 2.6 for the purpose of finalizing and executing such escrow agreement (with the arbitrator being someone with expertise in software transactions and/or the negotiation of escrow agreements with
respect thereto and with each Party submitting their last proposed draft of the escrow agreement with their Support Memorandum thereunder). 
  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
 8 

 2.5 Liquidated Damages. 
 2.5.1 The Parties acknowledge that Hansen is relying on Luna performing its obligations under Section 2.1 above in order to
provide Hansen with important technical solutions that are critical to Hansen’s business and that Hansen would suffer significant harm, and lose the benefit of a critical development and supply arrangement, if Luna fails to meet its obligations
under Section 2.1. The Parties acknowledge that the liquidated damages set forth in this Section 2.5 are reasonable under the circumstances existing on the Effective Date and reasonably approximate the amount of damage that would be
sustained by Hansen as a result of Luna’s failure to meet its obligations under Section 2.1, and that it is impracticable or extremely difficult to determine the actual damages that would be sustained by Hansen as a result thereof. The
Parties further acknowledge and agree that the amount of the liquidated damages set forth in this Section 2.5 is not a penalty. If a court of competent jurisdiction nonetheless determines, by a final, non-appealable judgment, that the amount of
the liquidated damages exceeds the maximum amount permitted by law, then the amount of the liquidated damages shall be reduced to the maximum amount permitted by law in the circumstances, as determined by such court of competent jurisdiction.

 2.5.2 In the event Luna breaches Section 2.1 of this Agreement and (a) Luna fails to cure such breach
within sixty (60) days after notice thereof from Hansen to Luna describing such breach in reasonable detail as well as those steps known to Hansen, if any, that Luna could take to cure such breach (or, within only thirty (30) days after
such a notice with respect to a second (same or similar) breach of Section 2.1 described in such a Hansen notice in the event a first breach of the same or similar nature subject to a Hansen notice hereunder was duly cured by Luna), or
(b) such breach is the third (same or similar) breach of Section 2.1 described in a Hansen notice of breach following Luna’s timely cure of two prior breaches of the same or similar nature described in previous Hansen notices
hereunder, then, in the case of either (a) or (b), Luna shall pay Hansen without offset, recoupment or defense, which are hereby waived by Luna, liquidated damages in the amount of Ten Million Dollars ($10,000,000) plus the amount of
Development Fees actually paid by Hansen pursuant to Section 4.1 below, due and payable within five (5) days after the end of the applicable cure period described above (in the case of (a)), or, with respect to the third breach under (b),
within five (5) days of Hansen’s notice referencing such third breach. In the event that Luna disputes that Luna has breached Section 2.1 of the Agreement or disputes that it has failed to cure such breach within the applicable cure
period (or Luna otherwise disputes the payment of liquidated damages that Hansen claims are due hereunder), either Party may by written notice submit the matter to resolution pursuant to Section 2.6 below. For the avoidance of doubt, if Luna
breaches Section 2.1 but subsequently cures such breach and/or achieves the next Development Milestone on a timely basis, in either case prior to a notice of breach from Hansen under this Section 2.5.2, Hansen shall thereupon have no right
to provide notice of such breach to Luna under this Section 2.5.2. 
 2.5.3 [****]. 
 2.6 Certain Development Disputes. If either Party has any dispute regarding Luna’s performance under Section 2.1
above, or any failures with respect thereto (including the payment of liquidated damages under Section 2.5 and any dispute regarding if and when a given Development Milestone is achieved or otherwise with respect to payments owed under
Section 4.1 (without limiting Section 4.2)) or otherwise pursuant to Sections 2.4, 3.3 and 3.8, then prior to taking any other action with respect to such dispute (e.g., litigation), except as may be required to preserve a Party’s
rights with respect to the dispute process described in the Amended Plan, the complaining Party shall refer the dispute to the Chief Executive Officers of the Parties for good-faith discussions over a period of not less than [****] days. Each Party
will make such executives reasonably available for such discussions. If the 
  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
 9 

 
Parties are unable to resolve any such dispute through such discussions within such [****] days, then either Party may initiate resolution of the matter in accordance with the following expedited
dispute resolution process (which shall be the exclusive dispute resolution process for any such dispute, except for, to the extent applicable, the dispute process described in the Amended Plan). Upon either Party’s request at such point, the
Parties shall submit such dispute to arbitration proceedings under the Comprehensive Arbitration Rules and Procedures of [****] as modified by this Section. The arbitration shall take place in New York City, New York before a single arbitrator. The
Parties shall jointly select the arbitrator, and should they fail to agree on such arbitrator within [****] days of this Section being invoked, the Parties shall request that [****] appoint an appropriate arbitrator who shall be a neutral,
independent and impartial individual with expertise in the development of medical devices. Within [****] days after an arbitrator is selected (or appointed, as the case may be), each Party will deliver to both the arbitrator and the other Party a
memorandum (the “Support Memorandum”) in support of its position with respect to the dispute (including any data or information in support thereof). Within [****] days after receipt of the other Party’s Support Memorandum, each
Party may submit to the arbitrator (with a copy to the other Party) a rebuttal to the other Party’s Support Memorandum. Neither Party may have communications (either written or oral) with the arbitrator other than for the sole purpose of
engaging the arbitrator or as expressly permitted in this Section; however, the arbitrator may convene a hearing if the arbitrator so chooses to hear oral argument and discussion regarding the dispute in question. The Parties shall direct the
arbitrator to decide the applicable dispute within [****] days after the arbitrator’s selection (or appointment, as the case may be). The decision of the arbitrator shall be final, binding, and unappealable and shall be deemed the decision of
the Parties hereunder and may be entered by any Party in a court of competent jurisdiction. Nothing in this Section 2.6 shall limit or restrict Hansen’s ability to enforce or defend its rights under this Agreement pursuant to the dispute
process described in the Amended Plan. 
 2.7 Further Assurances and Assistance. Each Party agrees to take or cause to be
taken such further actions, and to execute, deliver and file or cause to be executed, delivered and filed such further documents and instruments, and to obtain such consents, as may be reasonably required or requested by the other Party (to the
extent consistent with this Agreement and at the other Party’s expense) in order to effectuate fully the purposes, terms and conditions of this Agreement. Without limiting the foregoing, each Party shall provide the other Party with assistance,
information and cooperation reasonably requested by such other Party (and at such other Party’s expense) in connection with such other Party’s compliance with regulatory requirements and Applicable Laws with respect to the Luna Products
and/or End Products (with respect to the Luna Product portion thereof) and as required to obtain regulatory approvals and industry certifications for Luna Products or End Products (with respect to the Luna Product portion thereof), including without
limitation in connection with all regulatory filings, approvals and registrations for Luna Products and End Products (with respect to the Luna Product portion thereof). 
 3. Manufacture and Supply 
 3.1 Generally. If Hansen so
desires (but subject to Section 3.3.5 below), Luna shall manufacture and supply Luna Products to Hansen in such amounts requested by Hansen up to Hansen’s requirements of Luna Products for development and commercialization of Luna Products
or End Products, in accordance with the Specifications for such Luna Products. Luna represents and warrants that all Luna Products furnished to Hansen by Luna hereunder (a) shall be manufactured in accordance with all Applicable Laws (including
current Good Manufacturing Practice regulations and Quality System regulations, in each case promulgated by the US Food and Drug Administration (or its counterparts in jurisdictions outside the United States) and applicable International Conference
on Harmonization 
  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
 10 

 
manufacturing rules and guidelines), the ISO 13485 standard for Medical Devices and other generally recognized industry standards and certifications, such other ISO standards (if any) or UL
certifications (it being acknowledged that these other standards and certifications and the cost of meeting them will be incorporated into the Development Plan), (b) shall be free from defects in material or workmanship, and (c) shall
conform to the Specifications therefor in all material respects. If Luna wishes to use third party manufacturers to meet its manufacturing and supply obligations under this Article 3 for Luna Products, Luna shall provide Hansen with prior written
notice of Luna’s intent with respect thereto specifying the identity of the intended third party manufacturer and a draft agreement of the terms under which Luna proposes to engage such third party manufacturer, which draft agreement shall
contain at least the terms and conditions of this Article 3 and other applicable terms and conditions of this Agreement and shall (at Hansen’s option) include the right for Hansen to be included as a third party beneficiary to such agreement.
All such proposed third party manufacturers and agreements shall be subject to Hansen’s review and prior written consent before Luna may use, or validly conclude an agreement engaging, any third party manufacturer for Luna Products, and Luna
acknowledges that Hansen may reasonably condition or withhold its consent thereto on a case-by-case basis. This Section 3.1 shall not prevent Luna from including components in Luna Products purchased from third parties, subject to
Section 5.3. The Parties shall appoint project managers for purposes of the manufacture and supply arrangements set forth in this Article 3 with similar roles and authorities as the Project Managers described in Section 2.3 with respect to
the Development Program. For the avoidance of doubt, the manufacture and supply provisions in this Article 3 shall also include Luna Products that Hansen desires to order for its Subsidiaries and permitted sublicensees, and the provisions above and
below in this Article 3 shall be interpreted to allow for the purchasing of Luna Products from Luna by or for such Subsidiaries and sublicensees, as may be directed by Hansen from time to time. Except to the extent expressly provided for in
Section 3.3.5 and 3.8, nothing in this Agreement shall be construed (a) as imposing any requirement on Hansen (or its designees) to order or purchase Products or any other products in any quantity from Luna or (b) to limit
Hansen’s (or its designees’) ability to manufacture, or have a third party manufacture, Products or any other products. 
 3.2 Supply for Development. As and to the extent requested by Hansen, Luna shall manufacture and supply to Hansen, in accordance with Section 3.1, Luna Products for purposes of developing and/or obtaining regulatory approval of
the Luna Products or End Products (including for non-clinical and clinical studies) and other similar and related purposes at the Development Transfer Price, but not for commercial sale. Hansen shall keep Luna reasonably informed of its anticipated
requirements of Luna Products for such purposes, whether through the Project Manager meetings pursuant to Section 2.3 (if applicable), or otherwise. Hansen may order Luna Products for the development-related purposes described above under this
Section 3.2 from Luna by providing Luna with a binding purchase order indicating: (i) the quantities of Luna Product ordered (provided such quantities are consistent with the terms of this Agreement), (ii) the requested delivery date
[****], and (iii) a delivery location. Upon receipt of any such conforming purchase order, Luna shall manufacture and supply Luna Product in accordance therewith. Any term in such purchase order that is inconsistent with this Agreement shall
not be binding upon Luna; otherwise Luna shall send a confirmation to Hansen within [****] of receiving any such conforming purchase order. “Development Transfer Price” means [****]. 
 3.3 Commercial Supply 
 3.3.1 Commercial Supply Agreement. If Hansen commercially launches an End Product containing a Luna Product Luna shall manufacture and supply to Hansen up to Hansen’s requirements of Luna
Products (but subject to Section 3.3.5 below) for commercial sale (presumably as incorporated into End Products) in accordance with this Section 3.3. If Hansen so decides to launch such an End Product containing a Luna Product, the Parties
shall [****]. 
  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
 11 

 3.3.2 Commercial Transfer Price. Luna shall supply to Hansen Luna Products for
commercial sale (or marketing or promotional purposes) (presumably as incorporated into End Products) at the Commercial Transfer Price. [****]. 
 3.3.3 Quality Agreement. Promptly upon Hansen’s request, Hansen and Luna (and/or Luna’s third party manufacturer of Luna Product if applicable for regulatory purposes) shall negotiate and
execute a reasonable and customary quality agreement governing manufacture of Luna Product consistent with Applicable Laws (including regulatory requirements). 
 3.3.4 Advance Requirements Forecasts. Hansen shall provide Luna with reasonable advance notice (but no less frequently than on a rolling three month basis) of its forecasted supply needs so as to
allow Luna the ability to prepare to meet such supply needs. The Commercial Supply Agreement shall specify the extent to which such forecasts are binding and/or can be modified by Hansen. 
 3.3.5 [****]. 
 3.3.6 Other Provisions. The Commercial Supply Agreement shall contain provisions governing, inter alia, product recalls and withdrawals, inventory and buffer stocks, reasonably cost reduction efforts, facility licensures and permits
(and the maintenance thereof), adverse event procedures, term and termination provisions [****] and government inspections. 
 3.4 Delivery. All shipments and deliveries of Luna Products shall be made FCA at the delivery location specified in the purchase order therefor (Incoterms 2000). [****]. Luna shall provide appropriate documentation (including
documentation required to comply, and for Hansen to comply, with all Applicable Laws (including regulatory requirements) and to establish compliance with applicable industry standards and certifications with respect to such Luna Product) as well as
an invoice stating the Development Transfer Price or Commercial Transfer Price, as applicable, and describing in detail the calculation thereof, with all shipments of Luna Product hereunder. 
 3.5 Payment for Luna Product; Acceptance of Luna Product. All payments for Luna Products (at the Development Transfer Price or
Commercial Transfer Price, as the case may be) shall be due within [****] days from the date Luna delivers Luna Product to the delivery location specified in the applicable purchase order. Hansen shall have [****] days from the date of receipt by
Hansen to reject any Luna Product that does not conform to Hansen’s purchase order therefor (with respect to supply of Luna Products for commercial sale, to the extent the terms of such purchase order are consistent with those of the Commercial
Supply Agreement) or does not conform in all material respects to the Specifications therefor or otherwise does not comply in all material respects with the requirements of Section 3.1, or else such Luna Product shall be deemed accepted. If
Hansen rejects Luna Product in accordance with the foregoing, then, at Hansen’s election: (i) Hansen shall not be obligated to pay for such rejected Luna Product (and Luna shall refund to Hansen any amounts paid for such rejected Luna
Product and reimburse Hansen for any amounts incurred for return shipment or destruction of such rejected Luna Product if Luna requests return or destruction thereof) or (ii) Luna shall manufacture and deliver replacement conforming Luna
Product within a reasonably prompt period of time, which such replacement conforming Luna Product shall be subject to the terms of this Article 3, including the acceptance process set forth in this Section 3.5. 
  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
 12 

 3.6 Records; Inspections. Luna shall keep and maintain complete and accurate records,
reports and other documents as may be reasonably required to confirm its compliance with this Article 3 and Applicable Laws with respect to its manufacturing activities hereunder. Luna shall permit Hansen representatives to enter Luna’s
facilities upon reasonable prior notice and at reasonable intervals, during normal business hours for the purpose of reviewing such records, reports and documents and making quality assurance audits of the facilities and of the procedures and
processes used by Luna in storing, manufacturing and shipping Luna Products and for the purpose of confirming compliance with Article 3 and Applicable Laws. Luna shall ensure that any third party manufacturer to which Luna subcontracts manufacture
of Luna Products shall grant Hansen at least equivalent rights to inspect the facilities of such third party manufacturer. 
 3.7 Manufacturing Technology Transfer. Without limiting Hansen’s rights to manufacture or have manufactured Luna Products, in the event that (a) Luna is unable to meet Hansen’s reasonable supply needs of Luna Products
(to the extent in accordance with this Agreement) [****]. 
 3.8 [****] Supply Arrangements for Other Products.

 3.8.1 [****] Field. 
 (a) For the period of [****] years after the Effective Date, in the event that (i) Hansen elects to [****]. 
 (b) During the period beginning on the [****] anniversary of the Effective Date and continuing thereafter, [****]. 
 3.8.2 Non-Robotic Medical Field Outside Orthopedics, Endoluminal or Vascular. For a period of [****] years from the Effective Date, in the event that [****]. 
 4. Compensation 
 4.1 Development Fees. Hansen shall pay Luna for its development work done pursuant to Section 2.1 above in accordance with this Section 4.1. 
 4.1.1 [****] Fees. [****]. 
 4.1.2 Invoicing and Payment.
[****]. 
 4.1.3 [****]. 
 4.1.4 [****]. 
 4.2 Audit Luna shall keep and maintain complete and
accurate books, records and accounts as may be reasonably required to confirm its compliance with this Agreement and the amounts payable hereunder (including under Section 4.1 and under Article 3). Hansen shall have the right once per twelve
month period, upon reasonable advance notice and during normal business hours to have an independent third party auditor (one that is not otherwise engaged by Hansen for other auditing or tax purposes) audit such books, records and accounts to
verify the accuracy of the reports and amount of payments payable hereunder. [****]. 
  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
 13 

 5. Intellectual Property 
 5.1 Acknowledgement of License Agreement. The Parties acknowledge that they are concurrently entering into the separate License
Agreement governing the terms and conditions of licenses under certain Technology (and Intellectual Property Rights therein or thereunder) relevant to the development activities contemplated under this Agreement, including with respect to Fiber
Optic Shape Sensing/Localization Technology. Nothing herein shall limit the rights and licenses expressly granted to, acquired by or confirmed for Hansen or Luna in the License Agreement. For the avoidance of doubt, any Technology (and Intellectual
Property Rights therein or thereunder) developed, made, created, conceived or reduced to practice (in whole or in part) by or for Luna in connection with Luna’s development activities or performance under this Agreement shall be included in the
Licensed IP (including as used in Section 2.1 of the License Agreement) for all purposes under the License Agreement, including for purposes of the licenses granted to Hansen under the terms and conditions of the License Agreement (except, with
respect to Joint Patents, to the extent assigned to Hansen hereunder). Furthermore, the Parties acknowledge and agree that the licenses granted to Hansen under the License Agreement are essential to this Agreement and necessary for Hansen to enjoy
the benefits of the Development Program and other terms and conditions of this Agreement, and that, without such licenses, the purposes and performance of this Agreement would be entirely frustrated and materially impaired. Accordingly, without
limiting the terms and conditions of the License Agreement (or any rights or remedies for any breach thereof), the Parties agree that any termination of the licenses granted to Hansen under the License Agreement or any narrowing of (i) the
scope of such licenses or (ii) the degree of their exclusivity (which narrowing results in a material impairment of the purposes or performance of this Agreement and/or the License Agreement), shall be a material breach of this Agreement.

 5.2 New Inventions. To the extent a Party develops, makes, conceives or reduces to practice a new patentable invention
under the Development Program (“New Inventions”), subject to the License Agreement, ownership of the patent rights to such New Invention between the Parties shall be governed as follows: 
 5.2.1 Hansen Inventions. Hansen shall own all patent rights to any New Inventions that Hansen solely develops, makes, conceives or
reduces to practice (i.e., no employee or consultant of Luna is an “inventor” thereof under applicable patent law). Hansen shall have the sole right to file any patent application on any such New Invention and to control the prosecution
and enforcement thereof. Hansen shall promptly notify Luna in writing of any such New Inventions within thirty (30) days of documenting same. 
 5.2.2 Joint Inventions. Hansen shall own all patent rights to any New Inventions that Hansen and Luna jointly develop, make, conceive or reduce to practice (i.e., an employee or consultant of each
of Hansen and Luna is an “inventor” thereof under applicable patent law) (to the extent any patent application is filed thereon, together with any patents issuing thereon and other patent rights arising therefrom or claiming priority
thereto, a “Joint Patent”). Hansen shall have the sole right to file any patent application on any such New Invention (and to control the prosecution and enforcement thereof); provided that (i) Luna shall cooperate in the
filing of any such patent application to the extent consistent with applicable patent law and (ii) Hansen shall provide Luna with a copy of each such patent application. The Parties acknowledge that any Joint Patent(s) are subject to the
applicable terms and conditions of the License Agreement and Section 5.2.5 below. Each Party shall promptly notify the other in writing of any such New Inventions within thirty (30) days of documenting same. 
  

 14 

 5.2.3 Luna Inventions. Luna shall own all patent rights to any New Inventions that
Luna solely develops, makes, conceives or reduces to practice (i.e., no employee or consultant of Hansen is an “inventor” thereof under applicable patent law). Luna shall have the sole right to file any patent application on any such New
Invention and to control the prosecution and enforcement thereof, subject to the provisions below. The Parties acknowledge that any such New Inventions are subject to the applicable terms and conditions of the License Agreement and the
Intuitive-Luna License, to the extent applicable to such New Inventions (including Sections 5.1 and 5.2 of the License Agreement, but without limiting the additional terms and conditions regarding patent prosecution and enforcement below, and
including in any event the inclusion of such New Inventions and Intellectual Property Rights therein or thereto within the Licensed IP licensed to Hansen under the License Agreement). Luna shall promptly notify Hansen in writing of any such New
Inventions within thirty (30) days of documenting same. Upon Hansen’s reasonable request, Hansen shall have the right to review and provide input on all patent filings and responses regarding the New Inventions prior to their filing or
submission with any applicable patent office. Prior to dropping prosecution of any claim within any patent applications on any New Inventions, Luna shall notify Hansen thereof and Hansen, at is option, shall have the right to continue the
prosecution of such claim and Luna shall provide Hansen reasonable cooperation and assistance in connection therewith. Hansen shall have the sole and exclusive right to enforce any patents on New Inventions with respect to any infringement or
alleged infringement thereof in the [****] Field, the [****] Field and the [****] Field and the [****] Field, and the terms and conditions of Section 5.2(b) of the License Agreement shall otherwise apply with respect thereto. 
 5.2.4 Patent Ownership. Luna hereby assigns (and agrees to assign, identify, document and deliver) to Hansen all right, title and
interest in and to any Joint Patent. Luna shall execute and deliver all documents reasonably required by Hansen to evidence, perfect, record or enforce such assignment and/or the Joint Patents, and appoints Hansen as its attorney-in-fact to execute
and deliver such documents if Hansen is unable, after making reasonable inquiry, to obtain Luna’s signature. Hansen shall have the sole right (in its sole discretion) to control and oversee all filing, prosecuting, maintaining and enforcing any
and all Joint Patents at its own expense, and Luna shall reasonably cooperate with Hansen and provide all reasonable assistance (and execute such documents) in connection with any action Hansen may take with respect thereto, in all cases at
Hansen’s sole cost and expense. Notwithstanding anything to the contrary herein, the Parties agree that applicable patent law shall govern who is an inventor of any New Invention. In the event of any disagreement about ownership, inventorship
or similar matters arising out of this Agreement or otherwise related to New Inventions, the Parties hereby agree first to have their Chief Executive Officers or their designees meet and confer to attempt to resolve such disagreement. If such
disagreement is not resolved within [****] days of either party’s referral of such disagreement for resolution by such Chief Executive Officers or their designees, the Parties agree to submit such disagreement to final and binding arbitration
administered by the American Arbitration Association under its Patent Arbitration Rules before one single neutral arbitrator. Such arbitration shall occur in New York City, New York. The decision of the arbitrator shall be final, binding, and
unappealable and shall be deemed the decision of the Parties hereunder and may be entered by any Party in a court of competent jurisdiction. 
 5.2.5 [****] License to Joint Patents outside of [****] Fields. Hansen hereby grants Luna an irrevocable, perpetual, fully paid-up, royalty-free, nonexclusive, transferable, sublicensable,
worldwide license under the Joint Patent(s) to research, develop, make, have made, use, have used, import, sell, have sold, offer to sell, sell and transfer and otherwise commercialize and exploit under any such Joint Patents in all fields of use
outside the [****]. 
  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
 15 

 5.2.6 Retained Rights. For purpose of clarification and not of limitation (and
without limiting any other provisions of this Agreement or any terms and conditions of the License Agreement), nothing in this Section 5.2 shall assign the ownership of any Technology of any Party (other than the Joint Patents to Hansen as
provided above) nor limit the use of any Technology of any Party, except, with respect to Luna, to the extent any such use by Luna is covered by the valid and enforceable claims of any issued Joint Patent. 
 5.3 Third Party Technology. Luna shall inform Hansen prior to including Third Party Technology in or with any Luna Products (or
otherwise providing such Third Party Technology to Hansen in connection with the development of Luna Products hereunder). To the extent any such Third Party Technology is so included or provided, Luna shall provide Hansen with written notice
informing Hansen thereof and acknowledging Hansen’s rights thereto (and confirming such rights are as provided for in the License Agreement). To the extent any such Third Party Technology is required for Luna to manufacture and supply Luna
Products hereunder, and any royalties with respect thereto are to be included in the formula for the Development Transfer Price or the Commercial Transfer Price under Sections 3.2 and 3.3.2, respectively, then Hansen must provide its prior written
consent; provided, however, that if Hansen does not consent thereto, notwithstanding anything else herein to the contrary, Luna shall have no duty to supply such Luna Products. If Luna includes Third Party Technology with or in
any Luna Products (or otherwise provides such Third Party Technology to Hansen in connection with the development of Luna Products hereunder) without such Third Party Technology having been licensed or sublicensed to Hansen in accordance with the
foregoing, or if Luna infringes any third party patents or misappropriates any trade secrets in the course of its performance of the Development Program hereunder, then in all such cases, Luna shall indemnify, defend and hold harmless the Hansen
Indemnitees from and against any loss, damage, liability, judgment, fine, or amount paid in settlement (with Luna’s consent) and expense or cost of defense arising from any claim, demand, action, proceeding, in all such cases suffered or
incurred by the Hansen Indemnitees resulting from Hansen’s use and exploitation of such Third Party Technology. 
 6.
Representations and Warranties 
 6.1 By Hansen. Hansen hereby represents, warrants and covenants as follows:

 6.1.1 Hansen is a corporation duly organized, validly existing and in good standing under the laws of the state of
Delaware. 
 6.1.2 The execution, delivery and performance of this Agreement by Hansen (i) are within its corporate
powers, (ii) have been duly authorized by all necessary corporate action on Hansen’s part, and (iii) do not and shall not contravene or constitute a default under, and are not and shall not be inconsistent with, any law or regulation,
any judgment decree or order, or any contract, agreement or other undertaking applicable to Hansen. 
 6.2 By Luna. Luna
hereby represents, warrants and covenants as follows: 
 6.2.1 Luna is a corporation duly organized, validly existing
and in good standing under the laws of the state of Delaware. 
 6.2.2 The execution, delivery and performance of this
Agreement by Luna (i) are within its corporate power, (ii) have been duly authorized by all necessary corporate action on Luna’s part, and (iii) do not and shall not contravene or constitute a default under, and are not and shall
not be inconsistent with, any law or regulation, any judgment, decree or order, or any contract, agreement or other undertaking applicable to Luna. 
  

 16 

 6.2.3 Luna shall perform under Section 2.1 above in a professional and
workmanlike manner, consistent with industry standards, and in compliance with Applicable Laws. 
 6.2.4 Luna is not now
nor has in the past been debarred or disqualified or the subject of debarment or disqualification proceedings by any regulatory authority having jurisdiction and will not knowingly use in connection with its Development Program activities hereunder
any employee, consultant or investigator that has been debarred or disqualified or the subject of debarment or disqualification proceedings by any regulatory authority having jurisdiction. Luna covenants that it will notify Hansen, subject to any
confidentiality obligations and the preservation of attorney-client privilege, immediately after Luna’s receipt of information of any debarment or disqualification (or the initiation of any action or proceeding therefor) of any person
performing Development Program activities for Luna hereunder. 
 6.2.5 Luna has reviewed and approved the Development
Plan and the Development Milestones as of the Effective Date with the intent and expectation that such Development Plan and Development Milestones can be successfully achieved and Luna is not aware as of the Effective Date (as can be shown by clear
and convincing evidence) of any technical or scientific issues or realities that are likely to render the Development Plan and Development Milestones impractical or infeasible or likely to not be achieved within the proposed time frames and budget.

 6.3 Disclaimer. EXCEPT AS EXPRESSLY PROVIDED FOR IN THIS AGREEMENT, NEITHER PARTY MAKES, AND EACH PARTY HEREBY
DISCLAIMS, ANY AND ALL REPRESENTATIONS AND WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. 

7. Confidentiality 
 7.1 Definition. “Confidential Information” means all non-public written, visual, oral and electronic data and information disclosed by one Party (“Discloser”) to
the other Party (“Recipient”) under this Agreement or the License Agreement that relates to the Discloser’s business, technology, products, processes, techniques, research, development and marketing and is marked as
confidential or proprietary or disclosed under circumstances reasonably indicating that it is confidential or proprietary. All Hansen Licensed IP, Hansen New Inventions and unpublished patent applications for Joint Patents shall be Confidential
Information of Hansen and Hansen shall be the Discloser (and Luna the Recipient) thereof; and all Licensed IP and Luna New Inventions shall be Confidential Information of Luna and Luna shall be the Discloser (and Hansen the Recipient) thereof. All
Confidential Information (including without limitation all copies, extracts and portions thereof) shall remain the property of Discloser. Except as expressly agreed otherwise by the Parties, Recipient does not acquire any Intellectual Property
Rights under any disclosure hereunder except the limited right to use such Confidential Information in accordance with this Agreement and/or the License Agreement. 
 7.2 Restrictions. Recipient shall hold all Confidential Information of Discloser in strict confidence and shall not disclose any such Confidential Information to any third party except as expressly
provided in this Section 7.2. Recipient may disclose the Confidential Information of Discloser

  

 17 

 
only to regulatory authorities and employees, agents, contractors, Subsidiaries and actual and potential licensees and sublicensees (solely to the extent, in the case of any such licensee or
sublicensee, such Confidential Information to be disclosed is licenseable or sublicenseable to such licensee or sublicensee), in all such cases who have a reason to know such information for purposes of Recipient’s performance of its
obligations or exercise of its rights under this Agreement and/or the License Agreement and (except with respect to regulatory authorities) who are bound in writing by restrictions regarding disclosure and use at least as protective of Discloser as
the terms and conditions in this Agreement. Recipient shall not use any Confidential Information of Discloser for the benefit of itself or any third party or for any purpose other than to perform its obligations and exercise its rights under this
Agreement and/or the License Agreement. Recipient shall take at least the same degree of care that it uses to protect its own confidential and proprietary information and materials of similar nature and importance (but in no event less than
reasonable care) to protect the confidentiality and avoid the unauthorized use, disclosure, publication, or dissemination of the Confidential Information of Discloser. 
 7.3 Scope. The foregoing restrictions on disclosure and use shall not apply with respect to any Confidential Information of Discloser to the extent such Confidential Information: (a) was or
becomes publicly known through no wrongful act or omission of the Recipient or its Affiliates and their respective employees, agents and representatives; (b) was rightfully known by Recipient (except, for purposes of Luna as Recipient, with
respect to Joint Patents and Hansen Licensed IP) before receipt from Discloser; (c) becomes rightfully known to Recipient (except, for purposes of Luna as Recipient, with respect to Joint Patents and Hansen Licensed IP) from a source other than
Discloser without breach of a duty of confidentiality to Discloser or its Affiliates; or (d) is independently developed by Recipient (except, for purposes of Luna as Recipient, with respect to Joint Patents and Hansen Licensed IP) without the
use of or access to the Confidential Information of Discloser. In addition, Recipient may use or disclose Confidential Information of Discloser to the extent (i) approved by Discloser in writing or (ii) Recipient is legally compelled to
disclose such Confidential Information, provided, however, that prior to any such compelled disclosure, Recipient shall give Discloser reasonable advance notice of any such disclosure and shall cooperate with Discloser in protecting against any such
disclosure and/or obtaining a protective order narrowing the scope of such disclosure and/or use of such Confidential Information. 
 8. Indemnification; Limitation of Liability 
 8.1 By Hansen. Subject to Section 8.3, Hansen will
defend, indemnify and hold harmless Luna and its officers, directors, shareholders, employees, contractors and agents (collectively, the “Luna Indemnitees”) from and against any losses, damages, liabilities, judgments, fines,
amounts paid in settlement, expenses and costs of defense (including reasonable attorneys’ fees and witness fees) (collectively, “Losses”) resulting from any demand, claim, action or proceeding brought or initiated by a third
party (each a “Third Party Claim”) against any Luna Indemnitee(s) to the extent arising from: [****]. The foregoing indemnification shall not apply to the extent that such Losses arise from or relate to any Luna Indemnitee’s
gross negligence, intentionally harmful misconduct or breach of this Agreement or the Commercial Supply Agreement or to the extent Luna has an indemnification obligation pursuant to Section 8.2 for such Losses. 
 8.2 By Luna. Subject to Section 8.3, Luna will defend, indemnify and hold harmless Hansen and its Affiliates, officers,
directors, shareholders, licensees, designees, customers, employees, contractors and agents (collectively, the “Hansen Indemnitees”) from and against any Losses resulting from any Third Party Claim against any Hansen Indemnitee(s)
to the extent arising from: [****]. The foregoing indemnification shall not apply to the extent that such Losses arise from or relate to any Hansen Indemnitee’s gross negligence, intentionally harmful misconduct or breach of this Agreement or
the Commercial Supply Agreement or to the extent Hansen has an indemnification obligation pursuant to Section 8.1 for such Losses. 
  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
 18 

 8.3 Indemnity Procedures. The Party seeking indemnification hereunder shall give the
other Party (the “Indemnifying Party”): (a) prompt written notice of any Third Party Claim for which indemnification is sought; (b) sole control over the defense or settlement of such Third Party Claim; and
(c) reasonable assistance, at the Indemnifying Party’s expense, in the defense and settlement of the Third Party Claim. In no event, however, may the Indemnifying Party settle any Third Party Claim in a manner that diminishes the rights or
interests of the other Party under this Agreement and/or obligates the other Party to make any payment or take any action without the written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed. If
the Indemnifying Party fails to assume the defense, or if the Parties cannot agree as to the application of Section 8.1 or Section 8.2 in any given instance, then the Party seeking indemnification may conduct the defense and reserves the
right to seek indemnification under this Agreement upon resolution with the third party of the underlying matter. 
 8.4
Limitation of Liability. EXCEPT FOR BREACH OF ARTICLE 7 OR THE INDEMNIFICATION OBLIGATIONS SET FORTH IN SECTIONS 8.1 OR 8.2, AND EXCLUDING SECTION 2.5 AND WITHOUT LIMITING ANY LIQUIDATED DAMAGES PAYABLE THEREUNDER, IN NO EVENT SHALL A PARTY BE
LIABLE TO THE OTHER PARTY FOR SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, OR PUNITIVE DAMAGES OR LOST PROFITS ARISING OUT OF OR RELATED TO THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY. 
 9. Term and Termination 
 9.1 Term. This Agreement shall become effective on the Effective Date and shall remain in force and effect until [****]. 
 9.2 Termination by Hansen. In addition to any available remedies at law or in equity, this Agreement may be terminated by Hansen by
giving notice of termination to Luna: (a) in the event that Luna files or institutes any bankruptcy, liquidation or receivership proceedings, or in the event that Luna makes an assignment of a substantial portion of its assets for the benefit
of its creditors; provided, however, that, in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if Luna consents to the involuntary bankruptcy or such proceeding is not dismissed within sixty
(60) days after the filing thereof; (b) if Luna breaches [****] and fails to cure such breach in accordance with this Agreement within sixty (60) days after receipt of the initial notification by Hansen of such breach or such longer
period of time as provided in this Agreement; and (c) [****]. Except as expressly provided in the foregoing or in Section 2.5.3, Hansen shall have no right to terminate this Agreement. 
 9.3 Termination by Luna. In addition to any available remedies at law or in equity, this Agreement may be terminated by Luna
by giving notice of termination to Hansen: (a) in the event that Hansen files or institutes any bankruptcy, liquidation or receivership proceedings, or in the event that Hansen makes an assignment of a substantial portion of its assets for the
benefit of its creditors; provided, however, that, in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if Hansen consents to the involuntary bankruptcy or such proceeding is not dismissed within
sixty (60) days after the filing thereof; and (b) if Hansen breaches [****] and fails to cure such

  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
 19 

 
breach within thirty (30) days after receipt of notification by Luna of such breach (provided; however, that if Hansen disputes [****], Luna shall not have the right to terminate this
Agreement unless and until it is finally determined, in accordance with Section 2.6 (or the other applicable dispute resolution provisions of this Agreement) that Hansen is obligated to [****] and Hansen subsequently fails to cure such breach
(e.g., [****]), within thirty (30) days of such final determination (it being understood that Luna shall not have the right to terminate this Agreement if Hansen so cures following such final determination in dispute resolution). Except as
expressly provided in the foregoing, Luna shall have no right to terminate this Agreement. 
 9.4 Effect of Termination.
Expiration or termination of this Agreement (including under Section 2.5) for any reason shall not release either Party from any obligation or liability which, at the time of such expiration or termination, has already accrued to the other
Party or which is attributable to a period prior to such expiration or termination. The following Sections and Articles shall survive the expiration or termination of this Agreement for any reason: Section 2.4, 2.5, 2.6, Article 5, Article 7,
Article 8, Article 9, and Article 10. 
 10. Miscellaneous 
 10.1 Entire Agreement. Subject to Section 10.6 below, this Agreement (and its Exhibits), together with the Settlement Agreement,
the other Settlement Documents, and the Amended Plan and Confirmation Order, contain the entire agreement and understanding of the Parties with respect to the subject matter hereof, and supersede and merge all prior and contemporaneous
understandings and agreements between the Parties, whether written or oral, with respect to such subject matter. This Agreement shall not be modified, amended or cancelled other than in a writing signed by authorized representatives of both Parties.

 10.2 No Implied Waiver. Any waiver of any obligation under this Agreement or any other Settlement Document must be in
writing. The failure of either Party to enforce at any time any provision of or right under this Agreement shall not be construed to be a waiver of such provision or right or any other provision, and shall not affect the right of such Party to
enforce such provision or right or any other provision. No waiver of any breach hereof shall be construed to be a waiver of any other breach. 
 10.3 Assignment. This Agreement and the rights of the Parties hereunder may not be assigned by either Party to this Agreement without the prior written consent of the other Party; provided,
however, this Agreement (along with the rights granted hereunder) may be assigned by either Party without the other Party’s consent as part of a merger, consolidation or acquisition of the assigning Party; 
 sale of all or substantially all the assets of the assigning Party; or a similar reorganization of the assigning Party. Subject to the foregoing, the
respective obligations of the Parties hereto shall bind, and the respective rights of the Parties shall inure to the benefit of, the Parties’ respective permitted assignees and successors. 
 10.4 Governing Law; Jurisdiction; Venue. 
 10.4.1 Choice of Law. This Agreement shall be governed by, and interpreted in accordance with: (a) the Bankruptcy Code, and (b) in the case of applicable nonbankruptcy law, the
laws of the State of Delaware, without regard to conflicts of laws, or applicable federal law as to a particular subject where federal law governs, such as for example, the Patent Act governing patents or the Copyright Act governing copyrights.

  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
 20 

 10.4.2 Bankruptcy Court Jurisdiction. Except as provided in Section 10.4.3 and
Section 10.4.4, any disputes arising under this Agreement, or related to the meaning, effect and interpretation of the Amended Plan, the Confirmation Order or this Agreement (which Agreement is a part of the Amended Plan and Confirmation
Order), shall be subject to the jurisdiction of the Bankruptcy Court. 
 10.4.3 Exceptions to Bankruptcy Court
Jurisdiction. In the event: (a) the Bankruptcy Court lacks or declines to exercise jurisdiction over a dispute arising under this Agreement, for any reason; (b) the reference of jurisdiction to the Bankruptcy Court is withdrawn, for
any reason; (c) the dispute or enforcement is related to any intellectual property rights of Hansen or Luna, including without limitation any alleged infringement or misappropriation or misuse thereof; or (d) the dispute or enforcement
arises from or with respect to any provision of, or incorporated into, any of Sections 2.1, 2.2, 2.3, 2.4, 2.5, 4, 5, or 6.3 of the License Agreement or causes of action relating thereto or arising therefrom, or any of Sections 2.1, 2.2, 3, 4, 5, 7,
8 or 10.3 of this Agreement or causes of action relating thereto or arising therefrom, then the state or federal courts for or in New Castle County, Delaware shall have jurisdiction over any disputes arising under or related to this Agreement.

 10.4.4 Alternative Dispute Resolution. Notwithstanding Sections 10.4.2 and 10.4.3 above and Section 10.4.5
below, in the event some provision of a particular Settlement Document expressly creates an alternative dispute resolution provision as to a particular type of dispute, such as Sections 2.6 or 5.2.4 of this Agreement (or provisions of this Agreement
expressly invoking Section 2.6), then such disputes shall be resolved as so specified in the applicable Agreement. 
 10.4.5 Consent to Jurisdiction. Each Party hereby (a) consents and submits to the venue and co-exclusive jurisdiction of the Bankruptcy Court and the courts of New Castle County in the State of Delaware and the Federal courts of
the United States sitting in such part of the District of Delaware (without prejudice to either the retained rights and jurisdiction of the Bankruptcy Court), (b) agrees that all claims may be heard and determined in such courts,
(c) irrevocably waives (to the extent permitted by applicable law) any objection that it now or hereafter may have to the laying of venue of any such action or proceeding brought in any of the foregoing courts, and any objection on the ground
that any such action or proceeding in any such court has been brought in an inconvenient forum, and (d) agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the
judgment or in any other manner permitted by law. Each of the Parties hereby consents to service of process by any party in any suit, action or proceeding in accordance with such applicable law. 
 10.4.6 Resolving Conflicts. If there is any question as to whether the proper jurisdiction or venue for any dispute is in the
Bankruptcy Court or in the Delaware Court, the Bankruptcy Court may decide that issue. 
 10.4.7 Miscellaneous. The
prevailing Party in any final judgment of any such controversy, claim or dispute, or the non-dismissing Party in the event of a dismissal without prejudice, shall be entitled to receive from the other Party the reasonable attorneys’ fees (and
all related costs and expenses) and all other costs and expenses paid or incurred by such prevailing Party in connection with such controversy, claim or dispute and in connection with enforcing any judgment or order with respect thereto. 

 

 21 

 10.5 Severability. If for any reason a provision of this Agreement, or portion
thereof, is finally determined to be unenforceable under Applicable Laws, that provision, or portion thereof, shall nonetheless be enforced, as to circumstances, persons, places and otherwise, to the maximum extent permissible by Applicable Laws so
as to give effect to the intent of the Parties, and the remainder of this Agreement shall continue in full force and effect. 
 10.6 Effect of Plan/Confirmation Order. The Parties agree that this Section 10.6(a) is a settlement proposal that shall apply only to the extent approved by the Confirmation Order. The Parties
each agree to use commercially reasonable efforts to support the full rights sought by the Parties hereunder, including without limitation by appropriate proffers or other proof in the plan confirmation process. To the maximum extent possible under
applicable law (as affected by the Confirmation Order), this Agreement is not an “executory contract” for the purposes of 11 U.S.C. § 365. Rather, this Agreement constitutes a settlement allocation and partition of intellectual
property and other rights disputed in the Litigation and in Hansen’s related claims in the Chapter 11 Case but resolved by the Amended Plan and the Confirmation Order. To the extent that a final judgment by a court of competent jurisdiction
rules otherwise than that, the executory parts of this Agreement (herein sometimes called a “Section 365(n) Contract”) shall be interpreted so that the greatest possible rights and licenses of the licensee Party thereto shall be
held to be “executed,” thereby minimizing any “executory” parts of the Agreement. As to any Section 365(n) Contract, the parties hereto acknowledge and agree that the rights and licenses granted by the licensor Party to the
licensee Party and its Affiliates hereunder are rights with respect to intellectual property (including without limitation “intellectual property” within the meaning of 11 U.S.C. § 101), and: (a) all reports, drawings, samples,
prototypes and other books and records and embodiments of the intellectual property shall be deemed “embodiments” of the intellectual property protected by 11 U.S.C. § 365 hereunder; (b) any Settlement Document or
obligations thereunder that the licensee Party designates as such an “agreement supplementary” to such Section 365(n) Contract in its discretion at any time before the Confirmation Hearing in a “Plan Supplement” to the
Amended Plan, shall be, to the extent permitted by applicable law (as affected by the Confirmation Order) and so designated by the licensee, an “agreement supplementary” to such Section 365(n) Contract, but no other Settlement
Document or obligations shall be an “agreement supplementary” to such Section 365(n) Contract; and (c) there are no “royalty payments” due from Hansen or Luna as a licensee under such Section 365(n) Contract or,
since 11 U.S.C. § 365(n)(2) applies only to the Section 365(n) Contract, but not to any “agreement supplementary” to such contract, under any such supplementary agreement. In the event of any conflict between (i) the
provisions of this Section 10.6(a), or (ii) the rights contemplated by 11 U.S.C. § 365(n), and the Amended Plan or the Confirmation Order, the Amended Plan and Confirmation Order shall govern and control. Hansen and Luna each shall be
deemed to have made a request for enforcement of all of its rights and licenses pursuant to 11 U.S.C. § 365(n)(4), without further action by either licensee Party. 
 10.7 Headings. The headings and captions used in this Agreement are for convenience only and shall not be considered in construing or interpreting this Agreement. 
 10.8 Interpretation. This Agreement has been negotiated by all Parties, and each Party has been advised by competent legal counsel.
This Agreement shall be interpreted in accordance with its terms and without any construction in favor of or against either Party. 
 10.9 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but which collectively shall constitute one and the same instrument. 
 10.10 Force Majeure. No Party shall be responsible for delays to the extent resulting from causes beyond such Party’s control,
including without limitation fire, explosion, flood, war, strike, crisis, terrorist attack, earthquake, power failure, or riot, provided that the nonperforming Party notifies the other Party thereof and uses commercially reasonable efforts to
mitigate or remove such causes of nonperformance. 
  

 22 

 10.11 Relationship of the Parties. Luna’s relationship with Hansen shall be that
of an independent contractor and nothing in this Agreement should be construed to create a partnership, joint venture, agency or employer-employee relationship between the Parties. Luna is not the agent of Hansen and is not authorized and shall not
have any authority to make any representation, contract or commitment on behalf of Hansen, or otherwise bind Hansen in any respect whatsoever. Luna (and its employees and agents) shall not be entitled to any of the benefits Hansen may make available
to its employees, such as group insurance, profit-sharing or retirement benefits. Luna shall be solely responsible for all tax returns and payments required to be filed with or made to any federal, state or local tax authority with respect to
Luna’s performance of services and receipt of amounts under this Agreement. Hansen may regularly report amounts paid to Luna with the Internal Revenue Service as required by law. Because Luna is an independent contractor, Hansen shall not
withhold or make payments for social security, make unemployment insurance or disability insurance contributions, or obtain worker’s compensation insurance on Luna’s (or its employees’ or agents’) behalf. Luna shall comply with,
and agrees to accept exclusive liability for its own non-compliance with all Applicable Laws regarding its employees, consultants, taxes, benefits and payroll, including obligations such as payment of all taxes, social security, disability and other
contributions based on amounts paid to Luna, its agents or employees under this Agreement. Luna hereby agrees to indemnify, hold harmless and defend Hansen against any and all such liability, taxes or contributions, including penalties and interest.

 10.12 Notices. Except as may be otherwise provided herein, all notices, requests, waivers, consents and approvals made
pursuant to this Agreement shall be in writing and shall be conclusively deemed to have been duly given (a) when hand delivered to the other Party; (b) when sent by facsimile, with receipt confirmation, to the number set forth below if
sent between 8:00 a.m. and 5:00 p.m. recipient’s local time on a business day, or on the next business day if sent by facsimile to the number set forth below if sent other than between 8:00 a.m. and 5:00 p.m. recipient’s local time on a
business day; or (c) the next business day after deposit with a national overnight delivery service, postage prepaid, addressed to the applicable parties as set forth below with next business day delivery guaranteed, provided that the sending
Party receives a confirmation of delivery from the delivery service provider. Each person making a communication hereunder by facsimile shall attempt to promptly confirm by telephone to the person to whom such communication was addressed each
communication made by it by facsimile pursuant hereto but the absence of such confirmation shall not affect the validity or delivery status of any such communication. A Party may change or supplement the addresses given below, or designate
additional addresses, for purposes of this Section by giving the other Party written notice of the new address in the manner set forth above. 
 If to Hansen Medical, Inc. 
 800 E. Middlefield Road 
 Mountain View, CA 94043 
 Attn: Arthur Hsieh 
 Facsimile: 650-404-5901 
 Email: Arthur_Hsieh@hansenmedical.com 
  

 23 

 If to Luna Innovations Inc. 
 One Riverside Circle, Suite 400 
 Roanoke, VA 24016 
 Attn: 
 Facsimile: 
 If to Luna Technologies, Inc. 
 One Riverside Circle, Suite 400

 Roanoke, VA 24016 
 Attn: 
 Facsimile: 
 10.13 Luna Party. For purposes of this Agreement, Luna
Innovations Inc. and Luna Technologies, Inc. may be treated by Hansen as one entity, such that, for example, a notice or consent from Luna Innovations Inc. shall be deemed a valid and effective notice or consent also from Luna Technologies, Inc.
(and vice versa) and a payment from Hansen to Luna Innovations Inc. shall fully satisfy Hansen’s obligation with respect to such payment hereunder as to both entities. Luna Innovations Inc. and Luna Technologies, Inc. shall exercise their
rights jointly under this Agreement, and will not take conflicting positions vis a vis Hansen. 
 [Signature Page Follows]

  

 24 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized
representatives as of the Effective Date. 
  

									
	 LUNA INNOVATIONS INCORPORATED
	 		 	HANSEN MEDICAL, INC.
					
	By:	 	  
	 		 	By:	 	  

					
	Name:	 	  
	 		 	Name:	 	  

					
	Title:	 	  
	 		 	Title:	 	  

				
	 LUNA TECHNOLOGIES, INC.
	 		 		 	
					
	By:	 	  
	 		 		 	
					
	Name:	 	  
	 		 		 	
					
	Title:	 	  
	 		 		 	

 Exhibit A 
 Development Milestones 
 [****] 
  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 

 Exhibit B 
 Development Plan 
 [****] 
  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONSLicense Agreement Between Hansen and Luna - Luna Innovations Incorporated

 Exhibit 10.49 
 CONFIDENTIAL TREATMENT REQUESTED 
 LICENSE AGREEMENT
BETWEEN HANSEN AND LUNA 
 This License Agreement between Hansen and Luna (“Agreement”) is dated and made
effective as of the Effective Date by and between Luna Innovations Incorporated, a Delaware corporation, together with Luna Technologies, Inc., a Delaware corporation (acting jointly and severally, individually and collectively,
“Luna”) and Hansen Medical, Inc., a Delaware corporation (“Hansen”). Individually, Luna and Hansen are referred to individually as a “Party” and collectively as the “Parties.”

 RECITALS 
 WHEREAS, (a) Luna Innovations Incorporated and Hansen entered into those certain Terms and Conditions of Sale and Service executed by Hansen on September 27, 2006 and Luna on
September 28, 2006 (the “Hansen-Luna Agreement”) and that certain Mutual Nondisclosure Agreement between Hansen and Luna Innovations Incorporated dated April 1, 2006 (the “NDA”), which NDA is acknowledged
below and which Hansen-Luna Agreement is amended and restated in its entirety as of the Effective Date by the applicable provisions of this Agreement (so that all surviving provisions constituting the Hansen-Luna Agreement as amended are contained
and set forth in this Agreement), and which Hansen-Luna Agreement, as so amended and restated, shall be incorporated into and made a part of that certain Confidential Settlement Agreement (the “Settlement Agreement”) created to
implement the Amended Plan (as defined below); and (b) the Hansen-Luna Agreement shall be interpreted in accordance with the applicable terms and conditions of this Agreement and otherwise in accordance with the Settlement Agreement and Amended
Plan, and such interpretation shall be effective as against any other party in interest in the Chapter 11 Case (as defined below) or other third party; 
 WHEREAS, Luna and Hansen are parties to the case Hansen Medical Inc. v. Luna Innovations Inc., No. 07-088551, in the Superior Court of the State of California, County of Santa Clara
relating to certain disputes arising out of the Hansen-Luna Agreement and/or the NDA (the “Litigation”); 
 WHEREAS, Luna and Hansen wish to settle the Litigation in the context of the First Amended Joint Plan of Reorganization of Luna Innovations Incorporated and Luna Technologies, Inc. under Chapter 11 of the Bankruptcy Code
(“Amended Plan”) in Luna’s Chapter 11 Case No. 09-71811 (“Chapter 11 Case”) pending in the U.S. Bankruptcy Court for the Western District of Virginia (“Bankruptcy Court”) and approved by
the Bankruptcy Court’s Order Confirming First Amended Joint Plan of Reorganization of Luna Innovations Incorporated and Luna Technologies, Inc. (“Confirmation Order”). This Agreement is one of the “Hansen Settlement
Documents” (as defined in the Amended Plan) referenced and incorporated in the Amended Plan and Confirmation Order; 
 WHEREAS, in connection with the settlement of the Litigation through the Amended Plan: (i) Luna agrees to grant a license to Hansen to certain intellectual property related to fiber optic shape sensing or localization
technologies, as provided hereinafter and Hansen desires to receive such license; (ii) Luna and Hansen desire to confirm Hansen’s ownership of certain intellectual property developed for, and assigned to, Hansen under the Hansen-Luna
Agreement and (iii) Hansen agrees to grant and/or confirm the grant of a license to Luna to certain existing intellectual property (including the intellectual property described in the foregoing clause (ii)), as provided hereinafter, and Luna
desires to receive such license, in all cases in accordance with the terms and conditions hereof; 
 WHEREAS, Luna and
Intuitive (as defined below) are entering into that certain License Agreement Between Intuitive and Luna (“Intuitive-Luna License”) as of the Effective Date to allow, among other things, Intuitive and Hansen to continue to work with
Luna to develop Fiber Optic Shape Sensing/Localization Technology within the Medical Robotics field (each as defined below); 

 WHEREAS, Hansen and Intuitive have entered into that certain Cross-License Agreement
dated as of September 5, 2005 (the “2005 Hansen-Intuitive Cross License”), and it is the intent of the Parties and Intuitive that such 2005 Hansen-Intuitive Cross License shall remain in full force and effect and the terms of
such 2005 Hansen-Intuitive Cross License shall in no way be modified, affected or superseded by this Agreement; 
 NOW,
THEREFORE, in view of the terms and conditions described below and for other valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereto agree as follows: 
 AGREEMENT 
 1. DEFINITIONS. The following initially capitalized words and phrases (and derivative forms of these capitalized words and phrases) shall have the stated meanings below. The terms “include,” “includes,”
“including” shall be deemed followed by the phrase “without limitation” regardless of whether followed by that phrase: 
 1.1 “Affiliates” means any corporation or other entity that is directly or indirectly controlling, controlled by or under common control with a Party. For purposes of this
definition, “control” of an entity means the direct or indirect ownership of securities representing fifty percent (50%) or more of the total voting power entitled to vote in elections of such entity’s board of directors or other
governing authority, or equivalent interests conferring the power to direct or cause the direction of the governance or policies of such entity. The meaning of “Affiliates” shall be subject to the terms and conditions of Section 6.3.

 1.2 “Colonoscopy Non-Robotic Field” means [****]. 
 1.3 “Created By Luna” means, with respect to Technology, patent rights or other intellectual or industrial property
rights, to the extent such Technology, patent rights and other intellectual or industrial property rights were developed, made, created, conceived, reduced to practice (in whole or in part) by employees of Luna or its Affiliates or by other
individuals or entities obligated to assign rights therein to Luna or an Affiliate of Luna (in all such cases whether solely or jointly with others), provided, however, that the meaning of “Created By Luna” shall be subject to the terms
and conditions of Section 6.3. 
 1.4 “Development and Supply Agreement” means that certain
Development and Supply Agreement being entered into by and between the Parties concurrently herewith. 
 1.5
“Effective Date” means the Effective Date of the Amended Plan after entry of the Confirmation Order by the Bankruptcy Court, which the Parties hereby confirm to be January 12, 2010. 
 1.6 “Endoluminal Non-Robotic Field” means [****]. 
 1.7 “Fiber Optic Shape Sensing/Localization Technology” or “FOSSL Technology” means [****].

  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 
 2 

 1.8 “Hansen Generated Luna Agreement IP” means all right, title and
interest (including patent rights, copyrights, trade secret rights, mask work rights, trademark rights and all other intellectual property and industrial property rights of any sort throughout the world) relating to any and all inventions (whether
or not patentable), works of authorship, mask works, designations, designs, know-how, ideas and information made or conceived or reduced to practice, in whole or in part, by Hansen under the Hansen-Luna Agreement in connection with the projects to
develop products specified in the exhibits to the Hansen-Luna Agreement (but not including any technology or intellectual property developed by Hansen prior to or otherwise independently of such projects). 
 1.9 “Hansen Licensed IP” means (a) the Hansen Patents; (b) the Hansen Generated Luna Agreement IP; and
(c) the Hansen-Luna Agreement IP. 
 1.10 “Hansen Patents” means patent applications listed on
Exhibit E hereto regarding certain Fiber Optic Shape Sensing/Localization Technology filed by Hansen as of the Effective Date with the United States Patent and Trademark Office (and/or under the PCT system), together with any renewal, division,
continuation, continued prosecution application or continuation-in-part (solely to the extent claiming priority back to the applications listed on Exhibit E) of any of such patent applications, any and all patents or certificates of invention
issuing thereon, and any and all reissues, reexaminations, extensions, divisions, renewals, substitutions, confirmations, registrations and revalidations of or to any of the foregoing, and any foreign counterparts of any of the foregoing, in each
case to the extent claiming or covering any Fiber Optic Shape Sensing/Localization Technology. 
 1.11 “Hansen
Products” means any Product for which Hansen or its Affiliates has received or is in the process of seeking regulatory approval to market from the Food and Drug Administration (“FDA”) (or any FOSSL Technology-enabled
component or subsystem thereof) which has been, is or will be developed by or for Hansen or its Affiliates, or manufactured by or for Hansen or its Affiliates, or sold by or for Hansen or its Affiliates. 
 1.12 “Hansen-Luna Agreement IP” means all right, title and interest (including patent rights, copyrights, trade
secret rights, mask work rights, trademark rights and all other intellectual property and industrial property rights of any sort throughout the world) relating to any and all inventions (whether or not patentable), works of authorship, mask works,
designations, designs, know-how, ideas and information made or conceived or reduced to practice, in whole or in part, by Luna under the Hansen-Luna Agreement in connection with the projects to develop products specified in the exhibits to the
Hansen-Luna Agreement (but not including any technology or intellectual property developed by Luna prior to or otherwise independently of such projects, including without limitation all technology and intellectual property identified on Exhibit 5 to
the Hansen-Luna Agreement). “Hansen-Luna Agreement IP” includes, but is not limited to, the technologies described in Exhibit A. 
 1.13 “Intuitive” means Intuitive Surgical, Inc., a Delaware corporation. 
 1.14 “Intuitive-Luna Agreement” means that certain Development and Supply Agreement dated June 11, 2007 between Intuitive and Luna Innovations Incorporated, as restated and
amended by Luna and Intuitive as of the Effective Date pursuant to the Amendment to the 2007 Development and Supply Agreement (the “Amendment”) in connection with entering into the Intuitive-Luna License. 
 1.15 “Intuitive-Luna License” has the meaning given to such term in the recitals. 
  

 3 

 1.16 “Intuitive Products” means any Product for which Intuitive or
its Affiliates has received or is in the process of seeking regulatory approval to market from the Food and Drug Administration (or any FOSSL Technology-enabled component or subsystem thereof) which has been, is or will be developed by or for
Intuitive or its Affiliates, or manufactured by or for Intuitive or its Affiliates, or sold by or for Intuitive or its Affiliates. 
 1.17 “Licensed IP” means the Licensed Patents and the Licensed Technology. 
 1.18
“Licensed Patents” means any and all patents, inventors’ certificates and patent applications throughout the world to the extent claiming, or which would (absent a license) be infringed by the manufacture, use or sale of,
any FOSSL Technology, in each case which are owned, licensed (with a right to sublicense) or otherwise controlled by Luna or its Affiliates (subject to Section 6.3) as of the Effective Date or thereafter (including without limitation those
listed patent applications and patents set forth in Exhibit B, and any patents or patent applications which claim, or which would (absent a license) be infringed by the manufacture, use or sale of, the subject matter in Exhibit C or any other FOSSL
Technology described in subsections (a) through (d) of Section 1.19 (Licensed Technology) below), together with any renewal, division, continuation, continued prosecution application or continuation-in-part of any of such patents,
certificates and applications, any and all patents or certificates of invention issuing thereon, and any and all reissues, reexaminations, extensions, divisions, renewals, substitutions, confirmations, registrations and revalidations of or to any of
the foregoing, and any foreign counterparts of any of the foregoing, in each case to the extent claiming, or which would (absent a license) be infringed by the manufacture, use or sale of, any FOSSL Technology. 
 1.19 “Licensed Technology” means any and all FOSSL Technology (together with all intellectual and industrial
property rights of any sort throughout the world therein or thereunder) other than the Licensed Patents, in each case which are owned, licensed (with a right to sublicense) or otherwise controlled by Luna or its Affiliates (subject to
Section 6.3) as of the Effective Date or thereafter, including without limitation (a) FOSSL Technology owned, licensed (with a right to sublicense) or otherwise controlled by Luna prior to the Effective Date, (b) FOSSL Technology
Created By Luna in connection with the Intuitive-Luna Agreement (whether before, on or after the Effective Date), (c) FOSSL Technology otherwise Created By Luna prior to, and owned or controlled by Luna or its Affiliates as of, the Effective
Date; (d) FOSSL Technology Created By Luna, and owned or controlled by or licensed to Luna or its Affiliates, under or in connection with Luna’s research agreement with the Office of Naval Research dated March 6, 2008 (Fiber Optics
Shape Sensing for DADS Arrays, N00014-08-C-0156). “Licensed Technology” includes, but is not limited to, any of the foregoing related to the technologies described in Exhibit A and in Exhibit C. 
 1.20 “Medical Fields” means the Medical Robotics Field, the Non-Robotic Medical Devices Field (including the
Colonoscopy Non-Robotic Field), the Orthopedics Field, the Vascular Non-Robotic Field and the Endoluminal Non-Robotic Field. 
 1.21 “Medical Robotics Field” means [****]. 
 1.22 “Non-Robotic Medical Devices
Field” means [****]. 
 1.23 “Orthopedics Field” means [****]. 
 1.24 “Product” means any device, instrument, diagnostic, therapeutic, product, system, application or services.

  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
 4 

 1.25 “SDOF Medical Robotics” means [****]. 
 1.26 “Subsidiaries” means, with respect to any entity, all other entities in which such aforementioned entity has a
controlling ownership interest (directly or indirectly) of at least fifty-one percent (51%) of the issued and outstanding equity interests of such other entities. 
 1.27 “Technology” means any technical information, know-how, processes, procedures, methods, formulae, protocols, techniques, software, computer code (including both object and
source code), documentation, works of authorship, data, designations, designs, devices, prototypes, substances, components, inventions (whether or not patentable), mask works, ideas, trade secrets and other information or materials, in tangible or
intangible form. 
 1.28 “Vascular Non-Robotic Field” means [****]. 
 1.29 “2005 Hansen-Intuitive Cross License” has the meaning given to such term in the recitals. 
 2. LICENSE GRANTS 
 2.1 By Luna. 
 (a) Medical Robotics Field. Subject to the provisions in this Section 2.1(a) below,
Luna hereby grants to Hansen and its Affiliates a co-exclusive, worldwide, transferable (subject to Section 6.3 below), royalty-free, fully paid-up, perpetual and irrevocable license under the Licensed IP to research, develop, make, have made,
use, have used, import, sell, have sold and otherwise commercialize and exploit Products, in each case solely within the Medical Robotics Field. The foregoing license shall be co-exclusive between Intuitive and Hansen, which for purposes of such
license means that each of Hansen (and its Affiliates) and Intuitive (and its Affiliates) shall enjoy all the rights of an exclusive licensee (but for the rights of the other), except that: (i) Hansen shall have no right to, and shall not,
license or sublicense any Licensed IP in the Medical Robotics Field except that Hansen shall have the right to sublicense (through one or multiple tiers) Licensed IP in the Medical Robotics Field solely (A) in connection with the development,
manufacture, use or sale of Hansen Products, (B) with respect to SDOF Medical Robotics for which Hansen will have the sole right to grant naked sublicenses to third parties (without any restrictions or interference from either Intuitive or
Luna) and Intuitive has no right to grant such naked sublicenses, and/or (C) as otherwise mutually agreed by Intuitive and Hansen and Luna, (ii) Intuitive shall have no right to, and shall not, license or sublicense any Licensed IP in the
Medical Robotics Field except that Intuitive shall have the right to sublicense (through one or multiple tiers) Licensed IP in the Medical Robotics Field solely in connection with the development, manufacture, use or sale of Intuitive Products or as
otherwise mutually agreed by Hansen and Intuitive and Luna, and (iii) Luna shall retain no rights to or under any Licensed IP within the Medical Robotics Field except (x) solely to provide services to Hansen as authorized by Hansen and/or
services to Intuitive as authorized by Intuitive and (y) solely to perform research and development activities pursuant to contracts with the United States government in the Medical Robotics Field (and to grant licenses to the applicable United
States government agency as required in connection therewith) but only with the prior written approval of both Hansen and Intuitive, which approval may be given or withheld in the sole discretion of both Hansen and Intuitive, and Luna shall provide
to Hansen and Intuitive for their review a copy of each such proposed United States government contract so that they can each evaluate whether or not to approve such activities and/or license grants. To the extent any Licensed IP or Product has any
application or use in both the Medical Robotics Field and any other field, this Section 2.1(a) shall not, and is not intended to, prohibit, limit or restrict any such application or use (including development, manufacture, use, offer for sale
or sale) in such other field(s), subject to the other provisions (including license grants) in the other sections of this Agreement. 
  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
 5 

 (b) Non-Robotic Medical Devices Field. Subject to the provisions in this
Section 2.1(b) below, Luna hereby grants to Hansen and its Affiliates a co-exclusive, worldwide, transferable (subject to Section 6.3 below), royalty-free, fully paid-up, perpetual and irrevocable license under the Licensed IP to research,
develop, make, have made, use, have used, import, sell, have sold and otherwise commercialize and exploit Products, in each case solely within the Non-Robotic Medical Devices Field (which includes, for the avoidance of doubt, the Colonoscopy
Non-Robotic Field). The foregoing license shall be co-exclusive between Hansen and Luna, which for purposes of such license means that each of Hansen (and its Affiliates) and Luna (and its Affiliates) shall enjoy all the rights of an exclusive
licensee (but for the rights of the other hereunder), except that: (i) Hansen shall have the right to sublicense such license through one or multiple tiers in connection with the development, manufacture, use or sale of any Products (i.e.,
naked sublicenses are allowed), and (ii) Luna shall have the right to license the Licensed IP within the Non-Robotic Medical Devices Field through one or multiple tiers in connection with the development, manufacture, use or sale of any
Products (i.e., naked licenses are allowed). For purposes of clarity, subject only to the foregoing grant to Hansen and its Affiliates, Luna hereby reserves for itself and its Affiliates all of Luna’s other rights and interests in and to the
Licensed IP in the Non-Robotic Medical Devices Field, including, without limitation, the right under the Licensed IP to research, develop, make, have made, use, have used, import, sell, have sold and otherwise commercialize and exploit Products
within the Non-Robotic Medical Devices Field. Notwithstanding the foregoing, the license granted in this Section 2.1(b) shall be non-exclusive with respect to any Licensed Technology that constitutes “Intuitive New Intellectual
Property” as defined in the Intuitive-Luna Agreement. 
 (c) Orthopedics Field; Vascular Non-Robotic Field. Subject
to the provisions in this Section 2.1(c) below, Luna hereby grants to Hansen and its Affiliates an exclusive (even as to Luna and Intuitive), worldwide, transferable (subject to Section 6.3 below), royalty-free, fully paid-up, perpetual
and irrevocable license (with the right to sublicense through one or multiple tiers) under the Licensed IP to research, develop, make, have made, use, have used, import, sell, have sold and otherwise commercialize and exploit Products in each case
solely within the Orthopedics Field and the Vascular Non-Robotic Field (i.e., naked sublicenses within such fields are allowed). Luna shall retain no rights to or under any Licensed IP within the Orthopedics Field or within the Vascular Non-Robotic
Field except (i) solely to provide services to Hansen as authorized by Hansen and (ii) solely to perform research and development activities pursuant to contracts with the United States government in the Orthopedics Field or in the
Vascular Non-Robotic Field (and to grant licenses to the applicable United States government agency as required in connection therewith) but only with the prior written approval of Hansen, which approval may be given or withheld in Hansen’s
sole discretion, and Luna shall provide to Hansen for its review a copy of each such proposed United States government contract so that Hansen can evaluate whether or not to approve such activities and/or license grants. To the extent any Licensed
IP or Product has any application or use in the Orthopedics Field and any other field(s) (other than the Vascular Non-Robotic Field) or the Vascular Non-Robotic Field and any other field(s) (other than the Orthopedics Field), this
Section 2.1(c) shall not, and is not intended to, prohibit, limit or restrict any such application or use (including development, manufacture, use, offer for sale or sale) in such other field(s), subject to the other provisions (including
license grants) in the other sections of this Agreement and subject to provisions (including license grants) of the Intuitive-Luna License. Notwithstanding the foregoing, the license granted in this Section 2.1(c) shall be non-exclusive with
respect to any Licensed Technology that constitutes “Intuitive New Intellectual Property” as defined in the Intuitive-Luna Agreement. 
  

 6 

 (d) Endoluminal Non-Robotic Field. Subject to the provisions in this
Section 2.1(d) below, Luna hereby grants to Hansen and its Affiliates an exclusive (even as to Luna and Intuitive), worldwide, transferable (subject to Section 6.3 below), royalty-free, fully paid-up, perpetual and irrevocable license
(with the right to sublicense through one or multiple tiers) under the Licensed IP to research, develop, make, have made, use, have used, import, sell, have sold and otherwise commercialize and exploit Products in each case solely within the
Endoluminal Non-Robotic Field (i.e., naked sublicenses within the Endoluminal Non-Robotic Field are allowed). Luna shall retain no rights to or under any Licensed IP within the Endoluminal Non-Robotic Field except (i) solely to provide
services to Hansen as authorized by Hansen, (ii) solely to manufacture and have manufactured Products for Hansen within the Endoluminal Non-Robotic Field in accordance with the Development and Supply Agreement (and any commercial supply
agreement entered into between the Parties in connection therewith), and (iii) solely to perform research and development activities pursuant to contracts with the United States government in the Endoluminal Non-Robotic Field (and to grant
licenses to the applicable United States government agency as required in connection therewith) but only with the prior written approval of Hansen, which approval may be given or withheld in Hansen’s sole discretion, and Luna shall provide to
Hansen for its review a copy of each such proposed United States government contract so that Hansen can evaluate whether or not to approve such activities and/or license grants. To the extent any Licensed IP or Product has any application or use in
the Endoluminal Non-Robotic Field and any other field(s), this Section 2.1(d) shall not, and is not intended to, prohibit, limit or restrict any such application or use (including development, manufacture, use, offer for sale or sale) in such
other field(s), subject to the other provisions (including license grants) in the other sections of this Agreement and subject to provisions (including license grants) of the Intuitive-Luna License. Notwithstanding any of the foregoing to the
contrary, in the event the foregoing license to Hansen in the Endoluminal Non-Robotic Field is converted from exclusive to co-exclusive in accordance with the terms and conditions of Section 3.8.1 of the Development and Supply Agreement, then,
as of the date of such conversion, the rights of Hansen and Luna under the Licensed IP within the Endoluminal Non-Robotic Field shall be the same as the rights of Hansen and Luna under the Licensed IP within the Non-Robotic Medical Devices Field in
accordance with Section 2.1(b). Notwithstanding the foregoing, the license granted in this Section 2.1(d) shall be non-exclusive with respect to any Licensed Technology that constitutes “Intuitive New Intellectual Property” as
defined in the Intuitive-Luna Agreement. 
 (e) Certain Manufacturing Arrangements. The Parties acknowledge that they
have agreed to certain manufacturing arrangements within the Endoluminal Non-Robotic Field and the Non-Robotic Medical Field pursuant to and in accordance with the terms and conditions of Section 3.8 of the Development and Supply Agreement.

 2.2 Hansen-Luna Agreement IP; License Grants by Hansen. 
 (a) Hansen-Luna Agreement IP. Luna hereby acknowledges, agrees and confirms that, pursuant to Section 5 of the Hansen-Luna
Agreement: (i) Hansen owns all right, title and interest in and to the Hansen-Luna Agreement IP and all Hansen-Luna Agreement IP has been assigned to Hansen pursuant to the Hansen-Luna Agreement as of the date when such Hansen-Luna Agreement IP
was first Created By Luna thereunder; and (ii) Luna agreed to assist Hansen in protecting certain of its intellectual property, and accordingly, but without in any way limiting or expanding such agreement, Luna shall reasonably cooperate with
Hansen to the extent set forth in the next two sentences (which the Parties acknowledge are the same in substance and scope as the last two sentences of the second paragraph of such Section 5 of the Hansen-Luna Agreement and restate and amend
such last two sentences). Luna shall further assist Hansen, at Hansen’s expense, to further evidence, record and perfect such assignments of the Hansen-Luna Agreement IP, and to perfect, obtain, maintain, enforce, and defend

  

 7 

 
any rights assigned. Luna hereby irrevocably designates and appoints Hansen as its agents and attorneys-in-fact, coupled with an interest, to act for and on Luna’s behalf to execute and file
any document and to do all other lawfully permitted acts to further implement the foregoing intellectual property rights with the same legal force and effect as if executed by Luna. 
 (b) License from Hansen Outside the Medical Robotics Field. Subject to the provisions in this Section 2.2(b) below, Hansen
hereby grants to Luna and its Affiliates a nonexclusive, worldwide, transferable (subject to Section 6.3 below), royalty-free, fully paid-up, perpetual and irrevocable license (with the right to sublicense through one or multiple tiers, i.e.,
naked sublicensing is allowed) under the Hansen Licensed IP to research, develop, make, have made, use, have used, import, sell, have sold and otherwise commercialize and exploit Products, in each case solely outside the Medical Robotics Field,
outside the Orthopedics Field, outside the Vascular Non-Robotic Field and outside the Endoluminal Non-Robotic Field (except that such license to Luna shall also extend within such excluded fields solely to the extent of the scope of Luna’s
retained rights expressly described in Section 2.12.1(a)(iii)(x) and (y), Section 2.1(c)(i) and (ii); and Section 2.1(d)(i), (ii) and (iii) (and the last sentence of Section 2.1(d)), respectively). Furthermore, Hansen
hereby acknowledges, agrees and confirms that, pursuant to Section 5 of the Hansen-Luna Agreement, Hansen has granted to Luna a nonexclusive license under the Hansen Generated Luna Agreement IP and Hansen-Luna Agreement IP in all fields of use
outside the Medical Robotics Field (and the foregoing license under the Hansen Licensed IP includes, amends and restates such license pursuant to Section 5 of the Hansen-Luna Agreement); and the Parties agree that the foregoing license pursuant
to Section 5 of the Hansen-Luna Agreement is hereby amended to exclude the Orthopedics Field, the Vascular Non-Robotic Field and the Endoluminal Non-Robotic Field (except to the limited extent expressly described above, including by reference
to the last sentence of Section 2.1(d)). 
 2.3 Certain Intellectual Property Matters 
 (a) Retention of License. Once any Technology, patent rights or other intellectual property of a Party is included within any of the
licenses granted by this Agreement, such Technology and rights shall remain so included, and shall be and remain subject to the licenses granted. For example, and without limiting the foregoing, any Technology, patent rights or other intellectual
property of an Affiliate of Luna that is included within the Licensed IP at any given time shall remain so included, and shall be and remain subject to the licenses granted to Hansen, even if and after such Affiliate entity ceases at some point to
meet the definition of an Affiliate of Luna. As another example, and without limiting the foregoing (or Section 6.3), any assignment of, foreclosure on, or similar action with respect to, any Technology, patent rights or other intellectual
property that is included within the Licensed IP (or Hansen Licensed IP as the case may be) shall be subject to the licenses granted by this Agreement and shall not result in the termination of or restriction on such licenses and such licenses shall
survive any such assignment, foreclosure or similar actions. 
 (b) Intuitive-Luna Agreement Related Matters; Development
and Supply Agreement Related Matters. 
 (i) Intuitive-Luna Agreement Related Matters. The terms of the
Intuitive-Luna Agreement shall remain in full force and effect except as modified by the Amendment or by the Intuitive-Luna License. It is intended by the Parties that the Intuitive-Luna Agreement, as amended by the Amendment, be consistent with the
licenses granted in Section 2.1 of this Agreement, the corresponding license granted by Luna to Intuitive in Section 2.1 of the Intuitive-Luna License and the patent enforcement provisions of Article 5 herein and Article 4 of the
Intuitive-Luna License. Accordingly, Luna agrees that the Amendment shall provide that, (i) any exclusive licenses within the

  

 8 

 
Medical Robotics Field granted by Luna to Intuitive under the Intuitive-Luna Agreement (including under Sections 4.1 and 4.2 of the Intuitive-Luna Agreement) shall be modified to the extent
required to allow for the co-exclusive license granted by Luna under the Licensed IP to Hansen in this Agreement and to Intuitive in the Intuitive-Luna License; (ii) the provisions of the Intuitive-Luna Agreement (including Sections 4.2 and
14.2.1 of the Intuitive-Luna Agreement) shall be modified to eliminate any restrictions or prohibitions on Luna to develop and manufacture products for Hansen and otherwise perform its obligations under the Development and Supply Agreement; and
(iii) any provisions regarding the enforcement of Licensed Patents within the Intuitive-Luna Agreement (such as Section 9.7) shall be subject to and governed by Article 5 of this Agreement and Article 4 of the Intuitive-Luna License with
respect to such Licensed Patents. The foregoing matters are and shall be incorporated into the Amended Plan (or, alternatively, into a motion to assume the Amendment) and the Confirmation Order as well as into the Amendment. Luna agrees that it may
not amend, rescind or terminate the provisions in the Amendment effectuating the foregoing clauses (i) -(iii) or otherwise amend the Intuitive-Luna Agreement in a manner that amends, rescinds or terminates the foregoing clauses
(i) -(iii). 
 (ii) Development and Supply Agreement Related Matters. It is intended by the Parties and Intuitive
that the Development and Supply Agreement and this Agreement be consistent with the licenses granted in Section 2.1 of this Agreement, the corresponding license granted by Luna to Intuitive in Section 2.1 of the Intuitive-Luna License and
the patent enforcement provisions of Article 5 herein and Article 4 of the Intuitive-Luna License. Accordingly, Hansen and Luna agree not to amend the Development and Supply Agreement or this Agreement in a way that would (i) terminate or
rescind the licenses granted to Intuitive in Section 2.1 of the Intuitive-Luna License, (ii) amend, terminate or rescind the provisions in Article 5 of this Agreement or the patent enforcement provisions of the Development and Supply
Agreement in a way that conflicts with the current Article 5 of this Agreement and Article 4 of the Intuitive-Luna License, or (iii) restrict or prohibit Luna from developing or manufacture products for Intuitive under, or otherwise performing
its obligations under, the Intuitive-Luna Agreement. 
 (c) IP Created By Luna for Third Parties; No Conflicting Third Party
Agreements. To the extent any FOSSL Technology (and all patent rights and other intellectual property rights therein) acquired or Created By Luna independently or otherwise prior to the Effective Date (whether or not under agreements with
parties other than Hansen or Intuitive), and still owned by (or licensed to) Luna as of the Effective Date, would not otherwise be fully licensable to Hansen and Intuitive in accordance with the terms and conditions of Section 2.1 above, due to
some restriction, exclusive grant or other limitation in a third party agreement or otherwise (or due to the lack of some consent or approval not given), such restriction, exclusivity or limitation shall be removed, released and discharged (and such
consent or approval shall be deemed given) as of the Effective Date to the maximum extent allowed under Chapter 11 of the Bankruptcy Code or other applicable laws, so that such FOSSL Technology (and all patent rights and other intellectual property
rights therein) can be included within the Licensed IP and fully licensed to Hansen and Intuitive in accordance with the terms and conditions hereof. The foregoing is and shall be incorporated into the Amended Plan and the Confirmation Order. The
Parties acknowledge and agree to the foregoing. Furthermore, this Agreement and any license or right granted to Hansen hereunder shall be senior in right and time compared to any lien approved or created pursuant to the Amended Plan and the
Confirmation Order, so that no foreclosure under any such lien shall modify or terminate such licenses or rights of Hansen. Luna shall not modify the Intuitive-Luna Agreement or any other existing agreement with any third party or enter into any new
agreements with Intuitive or any other third party, or otherwise create or incur any obligation (whether by contract or otherwise), in a way that would terminate or narrow the scope or degree of exclusivity of the licenses granted to Hansen herein
(it being understood that, for example, the granting of rights by Luna outside of fields licensed to Hansen

  

 9 

 
herein or within the scope of Luna’s retained rights hereunder would not constitute a termination or narrowing of Hansen’s licenses granted hereunder) or the licenses or assignments
provided for in the Development and Supply Agreement, or in a way that would breach or result in the violation of any other material terms and conditions of this Agreement (or the Development and Supply Agreement); provided, that the foregoing (and
following sentence) is not intended to prevent Luna from granting a security interest or lien on the Licensed IP to any lender or a license to same in respect of the lender’s rights and remedies upon an event of default so long as any such
security interest, lien or license (or foreclosure thereon) is subject to, and does not terminate or narrow the scope or degree of exclusivity of, the licenses granted to Hansen herein. Luna shall not grant any right, license or interest in, to or
under the Licensed IP that terminates or narrows the scope or degree of exclusivity of the rights and licenses granted to Hansen in this Agreement. 
 (d) New IP Under Future Third Party Agreements. If, at any time after the Effective Date, Luna enters into any agreement with a third party granting rights to such third party under any of the
Licensed IP within, or involving a development project within, any of the Medical Fields (without limiting the co-exclusive and exclusive rights of Hansen in Section 2.1), then Luna shall secure the right to license to Hansen within the Medical
Robotics Field, Orthopedics Field, Vascular Non-Robotic Field and Endoluminal Non-Robotic Field hereunder any Fiber Optic Shape Sensing/Localization Technology (and all patent rights and other intellectual property rights therein) Created By Luna in
connection with such agreement in accordance with the terms of this Agreement, subject to Section 2.4 below (otherwise Luna shall not enter into such agreement). Luna shall use commercially reasonable efforts to secure the right to license
Fiber Optic Shape Sensing/Localization Technology and rights therein Created By Luna under such agreements to Hansen within the Non-Robotic Medical Devices Field (including the Colonoscopy Non-Robotic Field); provided, however, that
Luna shall have no duty to secure such right to license to Hansen to the extent within the third party’s field of development, e.g., if the development field is the Colonoscopy Non-Robotic Field, Luna shall have no duty to secure such a right
to license to Hansen within the Colonoscopy Non-Robotic Field, but would use commercially reasonable efforts to secure such right to license to Hansen for the rest of the Non-Robotic Medical Devices Field. Luna shall also use commercially reasonable
efforts to secure the right to license such Technology and rights Created By Luna under any other third party agreements (i.e., agreements outside the Medical Fields) to Hansen under the license grants to Hansen hereunder, in all such cases, subject
to Section 2.4 below. Furthermore, if Luna obtains a license to any Fiber Optic Shape Sensing/Localization Technology (and/or any patent rights and other intellectual property rights therein) and such license includes rights to sublicense
within any of the Medical Fields, Luna shall secure that such right to sublicense includes the right to sublicense to Hansen hereunder in accordance with the terms of this Agreement (i.e., Hansen shall not be excluded from such sublicensing rights
on a discriminatory basis), subject to Section 2.4 below. 
 (e) Acknowledgement Regarding Hansen Patents. Luna
hereby acknowledges and agrees that, if and to the extent any Luna personnel is an inventor of any subject matter claimed within any of the Hansen Patents, any rights or interests in such Hansen Patents that Luna would otherwise obtain therein are
assigned to Hansen, and to the extent Luna has not already done so, Luna hereby assigns any such rights or interests in such Hansen Patents to Hansen (which assignment confirmation shall be incorporated in the Settlement Agreement and the other
Hansen Settlement Documents, the Amended Plan and Confirmation Order). Accordingly, Luna shall reasonably cooperate with Hansen and provide all reasonable assistance (and execute such further reasonable documents) at Hansen’s cost and expense
in connection with any action Hansen may take to document Hansen’s ownership of the Hansen Patents or otherwise prosecute before a patent office to obtain a patent grant and maintain the Hansen Patents. 
  

 10 

 (f) Disclosure of Licensed IP. Periodically upon reasonable request from Hansen (no
more frequently than semi-annually until the [****] anniversary of the Effective Date, but without affecting any disclosure obligations under the Development and Supply Agreement), Luna’s and Hansen’s CTO’s (chief technological
officer or someone holding the comparable position) shall have a meeting to review the development of the FOSSL Technology for use in or in connection with the Medical Robotics Field or the Licensed IP, and, upon Hansen’s reasonable further
request to follow up on such meeting, Luna shall disclose to Hansen any Licensed IP and/or any FOSSL Technology for use in or in connection with the Medical Robotics Field as specified by Hansen in such request in the form of (1) copies of any
then-existing reports, summaries, memorandums, articles, invention disclosures, patents and patent applications, in each case (A) to the extent not already disclosed to Hansen and (B) in any event (i) excluding documents to the extent
covered by attorney-client privilege, (ii) excluding inventor notebooks, incomplete draft documents and mere email correspondence (but not excluding attached documents to the extent constituting the foregoing documents), and
(iii) excluding any information restricted from disclosure to Hansen under third party confidentiality obligations, or (2) Luna may prepare a document fulfilling such request that provides the substance of the responsive information that
otherwise would be provided pursuant to clause (1). Luna shall reasonably respond to limited, brief follow-up inquiries from Hansen regarding the items disclosed under (1) and/or (2) above for the purpose of confirming and complementing
the sufficiency of the disclosures above. The foregoing shall exclude software source code and related documentation and algorithms designed for the purpose of incorporation into source code (without limiting the provisions of the Development and
Supply Agreement). However, the foregoing obligation shall not require Luna to generate any new documents, reports or other materials that do not already exist (except to the extent Luna elects, in its sole discretion, to pursue (2) above
instead of (1)) and shall not require Luna to provide Hansen with training with respect to any inventions or Technology contained or described by the claims of such Licensed Patents. 
 (g) Clarification Regarding Copyrights. With respect to Technology licensed by Luna to Hansen under this Agreement that includes
software, works or authorship or copyrighted materials, such licenses shall include the right to copy, modify and make derivative works thereof (and the right to use any ideas, concepts, algorithms and other information contained therein) within the
fields and pursuant to the terms and conditions otherwise provided in this Agreement, regardless of when or whether provided or disclosed to Hansen. The foregoing shall not be construed to require the delivery or provision of any particular software
(or source code), works of authorship or copyrighted materials except to the extent specifically provided in the Development and Supply Agreement. 
 (h) Clarification Regarding Non-Licensed Technology. For purposes of clarity, the combination, incorporation or attachment of any Licensed IP or Hansen Licensed IP (as the case may be) as part of
or to other Technology that is not Licensed IP or Hansen Licensed IP (as the case may be) shall not result in the portion of the amalgamation that consists of the Technology that is not Licensed IP or Hansen Licensed IP becoming or being transformed
into Licensed IP or Hansen Licensed IP under this Agreement. 
 2.4 Third Party License Payments and Agreement Terms. If
Hansen’s practice of Licensed IP (including through Hansen’s manufacture, use or sale of Products covered thereby or grant of a sublicense covered thereby) that is in-licensed by Luna from third party licensors and sublicensed to Hansen
under Section 2.1 (Luna’s licenses of such third party Licensed IP being “Third Party Licenses” and such third party licensors being “Third Party Licensors”), results in a royalty, milestone or similar
payment becoming due to any Third Party Licensors, Hansen shall be responsible for such payments but solely to the extent the applicable provisions requiring (and setting forth the method for determining the

  

 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
 11 

 
amount and calculation of) such royalty, milestone and similar payments are disclosed to Hansen in writing in advance of Hansen incurring any such payments (such payments attributable to
Hansen’s practice of Licensed IP being, “Third Party Payments”). If permitted by such Third Party Licensors and Luna provides Hansen with the instructions therefor, Hansen shall directly pay such amounts to Third Party
Licensors on a timely basis. Otherwise, Hansen shall reimburse Luna for any such Third Party Payments actually paid by Luna to the applicable Third Party Licensor within ten (10) business days of receipt of an invoice therefor from Luna (or
within such period of time as may be agreed upon by the Parties after review of the applicable Third Party License). Hansen shall have no obligation to make or reimburse (and Luna shall be solely responsible for) any payments under or with respect
to any Third Party Licenses except for those Third Party Payments properly disclosed to Hansen in advance as provided above. Exhibit D sets forth a complete list of all Third Party Payments as of the Effective Date currently known to Luna. The
Parties shall reasonably cooperate with each other to provide such information and documents as is reasonably required to calculate, pay and report Third Party Payments. If Luna enters into any Third Party Licenses after the Effective Date, Luna
shall promptly disclose to Hansen the details of any Third Party Payments thereunder (but in any event at least thirty (30) days before any Third Party Payments would accrue) as well as all terms and conditions therein that are applicable to
Hansen or sublicensees generally. Hansen may choose in its sole discretion to exclude any Third Party License from the licenses granted to Hansen hereunder at any time by providing thirty (30) days prior written notice to Luna thereof, in which
case Hansen shall have no obligation to make or reimburse any Third Party Payments with respect to such excluded Third Party License (or comply with the applicable terms and conditions thereof with respect to periods following the effective date of
such notice) as of the end of such thirty (30) day notice period (except to the extent and for so long as any Third Party Payments continue to accrue even after such exclusion notice in accordance with terms disclosed to Hansen in advance as
provided above). If Hansen elects to exclude any Third Party License from the sublicenses to Hansen hereunder in accordance with the foregoing notice, such Third Party License shall be excluded from the Licensed IP for all purposes under this
Agreement. Unless Hansen has excluded any Third Party License in accordance with the foregoing, Hansen hereby agrees to comply with terms and conditions required of and applicable to sublicensees under any of the Third Party Licenses, but solely to
the extent disclosed to Hansen in advance. Luna shall maintain all Third Party Licenses (not excluded by Hansen in accordance with the foregoing) in full force and effect and comply with the terms and conditions thereof (except to the extent any
failure to do so would not terminate, limit or restrict Hansen’s sublicense of rights thereunder) and Luna shall not terminate or modify any such Third Party Licenses in a materially adverse manner that terminates, limits or restricts the
rights sublicensed to Hansen by Luna herein with respect to such Third Party License or in a manner that materially and adversely increases the obligations of Hansen (i) to make Third Party Payments or (ii) to comply with the terms and
conditions of such Third Party License. 
 2.5 Reservation of Rights. Except for the rights and licenses expressly
granted to, acquired by or confirmed for Hansen and its Affiliates hereunder and to Intuitive under Section 2.1 of the Intuitive-Luna License, Luna retains all right, title and interest in and to the Licensed IP and all of Luna’s other
intellectual and industrial property rights. Without limitation of the foregoing and subject at all times to the licenses granted to Hansen under this Agreement, the Parties confirm that Luna retains its rights to use, make and sell (and license)
any and all of its intellectual and industrial property rights (i) within technologies, applications and fields that do not involve FOSSL Technology (for example, nanotechnology, secure computing, industrial coating, flame retardants,
ultrasonic, and wireless technologies and applications) and (ii) subject to the licenses granted under Section 2.1 and licenses granted to Intuitive under the Intuitive-Luna License, within technologies, applications and fields outside the
Medical Fields that do involve FOSSL Technology, including, for example, industrial application, oil exploration, infrastructure, civil, aeronautics, naval, automotive, telecommunication and consumer 
  

 12 

 
products. Except for the rights and licenses expressly granted to Luna hereunder and under the Development and Supply Agreement, Hansen retains all right, title and interest in and to the
Hansen-Luna Agreement IP, the Hansen Licensed IP and all of Hansen’s other intellectual and industrial property rights. 
 3. PAYMENTS 
 3.1 Compensation from Hansen. The parties acknowledge and agree that the rights and
licenses granted by Luna to Hansen under this Agreement are provided in consideration for settlement of the Litigation and pursuant to and part of the Hansen Settlement Documents that are part of and implement the Amended Plan and are incorporated
into and made part of the Confirmation Order. Accordingly, among other things, the Parties acknowledge and agree that no payments, royalties or other compensation for the rights and licenses expressly granted to, acquired by or confirmed for Hansen
hereunder shall be due or payable by Hansen to Luna hereunder (but without limiting other payments and obligations that Hansen may owe under the terms of this Agreement). 
 3.2 Compensation from Luna. The parties acknowledge and agree that the rights and licenses granted by Hansen to Luna under this Agreement are provided in consideration for settlement of the
Litigation and pursuant to and part of the Hansen Settlement Documents that are part of and implement the Amended Plan and are incorporated into and made part of the Confirmation Order. Accordingly, among other things, the Parties acknowledge and
agree that no payments, royalties or other compensation for the rights and licenses expressly granted to, acquired by or confirmed for Luna hereunder shall be due or payable by Luna to Hansen hereunder (but without limiting other payments and
obligations that Luna may owe under the terms of this Agreement). 
 4. REPRESENTATIONS AND WARRANTIES; DISCLAIMERS;
INDEMNIFICATION 
 4.1 By Hansen. Hansen hereby represents, warrants and covenants as follows: 
 (a) Hansen is a corporation duly organized, validly existing and in good standing under the laws of the state of Delaware.

 (b) The execution, delivery and performance of this Agreement by Hansen (i) are within its corporate powers,
(ii) have been duly authorized by all necessary corporate action on Hansen’s part, and (iii) do not and shall not contravene or constitute a default under any law or regulation, any judgment decree or order, or any contract, agreement
or other undertaking applicable to Hansen or the Hansen-Luna Agreement IP. 
 (c) Hansen has the full right and
authority to grant (and/or confirm the grant of) the rights and licenses granted (and/or confirmed) by Hansen under Section 2.2 to Luna herein. 
 (d) To the best of Hansen’s knowledge as of the Effective Date, except for the Litigation and the Chapter 11 Case, there are no actions, suits, investigations, claims or proceedings pending or
threatened against Hansen relating to the Hansen-Luna Agreement IP or other Hansen Licensed IP. 
 (e) Aside from the
Development and Supply Agreement (which, among other things, amends and restates the Hansen-Luna Agreement) and this Agreement, there are no agreements between Luna and Hansen as of the Effective Date with respect to FOSSL Technology (other than the
NDA) or that would restrict or prevent the granting of the licenses granted by Luna to Intuitive in Section 2.1 of the Intuitive-Luna License or the granting the corresponding license granted by Luna to Hansen in Section 2.1 of this
Agreement. 
  

 13 

 (f) Aside from the Development and Supply Agreement, there are no amendments or
modifications to the Hansen-Luna Agreement. 
 (g) Hansen agrees not to amend the Cross License Agreement Between
Intuitive and Hansen of even date herewith in a way that would (i) terminate or rescind the licenses granted to Luna in Section 2.2(b) of this Agreement, or (ii) conflict with the provisions in Article 5 of this Agreement or the
patent enforcement provisions of the Development and Supply Agreement, or (iii) restrict or prohibit Luna from developing or manufacturing products for Intuitive under, or otherwise performing its obligations under, the Intuitive-Luna
Agreement. 
 4.2 By Luna. Luna hereby represents, warrants and covenants as follows: 
 (a) Luna is a corporation duly organized, validly existing and in good standing under the laws of the state of Delaware. 

(b) The execution, delivery and performance of this Agreement by Luna (i) are within its corporate power, (ii) have
been duly authorized by all necessary corporate action on Luna’s part, and (iii) do not and shall not contravene or constitute a default under any law or regulation, any judgment, decree or order, or any contract, agreement or other
undertaking applicable to Luna or the Licensed IP. 
 (c) Luna has the full right and authority to grant the rights and
licenses granted to Hansen in Section 2.1 herein. Without limiting the foregoing, as of the Effective Date, (i) Luna does not own, have a license to or otherwise control (and did not at any time own, have a license to or otherwise control)
any FOSSL Technology (or any patent rights and other intellectual property rights therein) that cannot be fully licensed to Hansen under the terms and conditions of this Agreement (within the full scope of the license grants to Hansen hereunder),
and (ii) Luna has not granted any right, license, or interest in, to or under the Licensed IP inconsistent with the rights and licenses granted to Hansen in this Agreement (other than under the Intuitive-Luna Agreement, without limiting
Section 2.3(b)). 
 (d) To the best of Luna’s knowledge as of the Effective Date, except for the Litigation
and the Chapter 11 Case, there are no actions, suits, investigations, claims or proceedings pending or threatened against Luna relating to the Licensed IP and appropriate notices of the Amended Plan and Confirmation Order have been served timely by
Luna on any person or entity who might possibly have any such claim. 
 (e) With the exception of Luna’s work with
Intuitive, Luna has not disclosed or made any use of any of the Hansen-Luna Agreement IP in connection with work for or with any customers, clients, business partners, or any other third party other than Hansen in the Medical Robotics Field.

 (f) As of the Effective Date, Luna has obtained all consents from third parties required to sublicense to Hansen
hereunder the rights licensed to Luna under the agreements listed on Exhibit D hereto. 
  

 14 

 (g) Luna has the full right and authority to agree to the modifications and
clarifications to the Intuitive-Luna Agreement as provided by Section 2.3(b) of this Agreement. 
 (h) Aside from
the Intuitive-Luna Agreement and the Intuitive-Luna License, there are no agreements between Luna and Intuitive as of the Effective Date with respect to FOSSL Technology or that would restrict or prevent the granting of the licenses granted by Luna
to Intuitive in Section 2.1 of the Intuitive-Luna License or the granting of the corresponding license granted by Luna to Hansen in Section 2.1 of this Agreement. 
 (i) Aside from the Amendment (which shall be consistent with Section 2.3(b)), there are no amendments or modifications to the
original Intuitive-Luna Agreement as of the Effective Date. 
 (j) Luna agrees not to not amend the Intuitive-Luna
License in a way that would (i) terminate or rescind the licenses granted to Hansen in Section 2.1 of this Agreement, (ii) conflict with the provisions in Article 5 of this Agreement or the patent enforcement provisions of the
Development and Supply Agreement, or (iii) restrict or prohibit Luna from developing or manufacture products for Hansen under, or otherwise performing its obligations under, the Development and Supply Agreement. 
 4.3 Disclaimer. EXCEPT AS EXPRESSLY PROVIDED FOR IN THIS AGREEMENT, THE OTHER SETTLEMENT DOCUMENTS, THE AMENDED PLAN AND THE
CONFIRMATION ORDER, NEITHER PARTY MAKES, AND EACH PARTY DISCLAIMS, ANY AND ALL REPRESENTATIONS AND WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT, INCLUDING WITHOUT LIMITATION WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND AS TO THE VALIDITY OF LICENSED PATENT CLAIMS, WHETHER ISSUED OR PENDING. NOTHING IN THIS AGREEMENT (OR ANY OTHER SETTLEMENT DOCUMENT, THE AMENDED PLAN AND CONFIRMATION ORDER) SHALL BE CONSTRUED
AS A REPRESENTATION MADE OR WARRANTY GIVEN BY EITHER PARTY THAT THE PRACTICE BY THE OTHER PARTY OF THE RIGHTS GRANTED BY THIS AGREEMENT WILL NOT INFRINGE THE PATENT OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY. 
 5. INTELLECTUAL PROPERTY 
 5.1 Prosecution and Maintenance of Licensed Patents. Luna shall file, prosecute and maintain all Licensed Patents in accordance with Luna’s then-current patent protection and maintenance
strategy/ies (determined in Luna’s reasonable discretion) with respect to its patent portfolio at Luna’s sole cost and expense. Luna shall provide Hansen, upon Hansen’s reasonable request, with copies of all material correspondence,
applications and filings with respect to the Licensed Patents, filed with, sent to or received from the applicable patent office (following the receipt, filing or submission thereof, as the case may be). If Luna decides to cease prosecution or
maintenance of any of the Licensed Patents, Luna shall first provide Hansen with written notice of such decision within a reasonable period (but at least forty-five (45) days if practicable) prior to any pending filing or maintenance fee
deadline of which it is aware so Hansen may take on behalf of Luna, at Hansen’s sole cost and expense, whatever reasonable action may be necessary with respect thereto so long as such action is not reasonably likely to be materially adverse to
Luna, as would be reasonably apparent at the time such action is taken (and Hansen shall notify Luna of such proposed actions prior to taking them). Hansen may, in its sole discretion, thereafter assume responsibility for such prosecution or
maintenance at its sole cost and

  

 15 

 
expense, and shall notify Luna in writing prior to assumption if it elects to assume such responsibility. In such event, Hansen shall provide Luna, upon Luna’s request, with copies of all
material correspondence, applications, and other filings with respect to any such Licensed Patents assumed by Hansen filed with, sent to or received from the applicable patent offices. In the event Hansen so elects to assume such responsibility for
a given Licensed Patent, Luna shall reasonably cooperate at Hansen’s sole cost and expense. If Hansen identifies any potential claims within the Licensed Patents which Luna has not and does not intend to file, prosecute or continue, Hansen, at
its option and sole cost and expense, shall have the right to do so on Luna’s behalf with Luna’s prior reasonable consent in each instance (not to be unreasonably withheld), and, in such case, Luna shall provide Hansen reasonable
cooperation and assistance in connection therewith, at Hansen’s sole cost and expense and Hansen shall keep Luna reasonably informed of material developments (including providing drafts of submissions for Luna’s review and comment prior to
filing). Hansen shall provide Luna, upon Luna’s request, with copies of all material correspondence, applications, and other filings with respect thereto filed with, sent to or received from the patent offices having jurisdiction. For the
avoidance of doubt, Hansen, as owner of the Hansen Licensed IP, shall have the sole rights to file, prosecute and maintain and the sole rights to enforce, any patents and patent rights within such Hansen Licensed IP, in Hansen’s sole
discretion. 
 5.2 Enforcement of Licensed Patents. 
 (a) In the Medical Robotics Field. Hansen shall have the right (but not the obligation) (along with Intuitive) to institute
enforcement actions against infringement or misappropriation or alleged infringement or misappropriation of the Licensed IP solely to the extent within the Medical Robotics Field, in each case at its own expense. If Hansen institutes such
enforcement, Hansen shall be the “Enforcing Party” and Intuitive shall be the “Non-Enforcing Party”; if Intuitive institutes such enforcement Intuitive shall be the “Enforcing Party” and Hansen
shall be the “Non-Enforcing Party.” The Enforcing Party shall notify Luna and the Non-Enforcing Party in writing of its decision to institute such enforcement action and shall keep them reasonably apprised of all developments in
such enforcement actions and consult with them regarding such enforcement activities, but the Enforcing Party shall not be required to obtain any approvals or consents to take such enforcement actions, subject to Section 5.2(e) below. Each of
Luna and the Non-Enforcing Party shall, at the Enforcing Party’s expense, reasonably cooperate with the Enforcing Party and provide all reasonable assistance in connection with any such enforcement action, including without limitation agreeing
to be named as a party to such action or having such action brought in its name by the Enforcing Party (at the Enforcing Party’s expense, including the cost of any fees and court costs) if and to the extent required for the Enforcing Party to
have the legal right to initiate such an enforcement action, subject to Section 5.2(e) below, including without limitation as an estate representative pursuant to 11 U.S.C. § 1123(b)(3) and otherwise pursuant to the Amended Plan. The
Enforcing Party shall retain all recoveries from such enforcement actions, provided that non-monetary recoveries shall inure to the benefit of both the Enforcing Party and the Non-Enforcing Party as an interested party to the extent of its interest.
No settlement, consent judgment or other voluntary final disposition of the action that involves an admission of Luna’s (or the Non-Enforcing Party’s) liability or wrongdoing, requires Luna (or the Non-Enforcing Party) to take or refrain
from taking any action or incur any payment obligations or other liabilities or otherwise binds Luna (or the Non-Enforcing Party) or that involves an admission of the invalidity or unenforceability of the Licensed IP or any other of Luna’s (or
the Non-Enforcing Party’s) intellectual property or that could reasonably be likely to restrict Luna (or the Non-Enforcing Party) from conducting its business, may be entered into without the express written consent of Luna (and, if applicable,
the Non-Enforcing Party), which consent shall not be unreasonably withheld. Notwithstanding any of the foregoing to the contrary, any patents within the Licensed Patents that are Created By Luna under the Development and Supply Agreement shall be
governed by Section 5.2(b) below (as if within the fields specified therein) with respect to the enforcement thereof (without limiting the licenses granted thereto hereunder). 
  

 16 

 (b) In the Orthopedics Field, Endoluminal Non-Robotic Field, and Vascular Non-Robotic
Field. Hansen shall have the sole right (but not the obligation) to institute enforcement actions against infringement or misappropriation or alleged infringement or misappropriation of the Licensed IP solely to the extent within the Orthopedics
Field, the Vascular Non-Robotic Field, or the Endoluminal Non-Robotic Field, including, if required to bring such action, as an estate representative pursuant to 11 U.S.C. § 1123(b)(3) (to the extent provided in the Confirmation Order), to the
extent required to bring such actions, and otherwise pursuant to the Amended Plan, in each case at its own expense. Hansen shall keep Luna reasonably apprised of all developments in such enforcement actions and shall consult with Luna regarding such
enforcement activities (but, for clarity, no approval or consent from Luna shall be required for Hansen to bring such enforcement actions). Luna shall, at Hansen’s expense, reasonably cooperate with Hansen and provide all reasonable assistance
in connection with any such litigation, subject to Section 5.2(e) below, including without limitation agreeing to be named as a party to such action or having such action brought in Luna’s name by Hansen (in each case at Hansen’s cost
and expense) if and to the extent required for Hansen to have the legal right to initiate such an enforcement action. Hansen shall retain all recoveries from such enforcement actions. No settlement, consent judgment or other voluntary final
disposition of the action that involves an admission of Luna’s liability or wrongdoing, requires Luna to take or refrain from taking any action or incur any payment obligations or other liabilities or otherwise binds Luna or that involves an
admission of the invalidity or unenforceability of the Licensed IP or any other of Luna’s intellectual property or that could reasonably be likely to restrict Luna from conducting its business, may be entered into without the express written
consent of Luna, which consent shall not be unreasonably withheld. 
 (c) In the Non-Robotic Medical Devices Field.
Except with respect to claims that fall within clause (a) or (b) above, each of Hansen and Luna shall promptly notify the other of any infringement or misappropriation of the Licensed IP within the Medical Fields of which it becomes aware,
and the Parties shall confer together with a view to agreeing upon a common cause of action. If they do not agree upon a common cause of action, then Luna shall have the initial sole right, but shall not be obligated, to institute and prosecute at
its own expense, legal actions for infringement or misappropriation of Licensed IP in the Medical Fields outside the Medical Robotics Field, Orthopedics Field, Vascular Non-Robotic Field, and/or Endoluminal Non-Robotic Field. If Luna elects
not to pursue such action, then Hansen shall have the right, but shall not be obligated, to prosecute at its own expense such action. In all such cases, all monetary recoveries obtained by the enforcing Party (after reimbursement of the
Parties’ expenses incurred with respect to such action) shall accrue to and shall be the sole property of such enforcing Party, provided that nonmonetary recoveries shall inure to the benefit of both Parties as an interested party to the extent
of its interest. The other Party, at the request and expense of the enforcing Party, shall reasonably assist in the prosecution of such suit (including by being named as a party to such suit if required for the enforcing Party to bring such action),
reasonably co-operate with respect thereto, have its employees testify when reasonably requested and make available relevant records, documents, drawings, information, and the like, subject to Section 5.2(e) below. No settlement, consent
judgment or other voluntary final disposition of any action brought under this Section 5.2(c) that involves an admission of the non-enforcing Party’s liability or wrongdoing, requires the non-enforcing Party to take or refrain from taking
any action or incur any payment obligations or other liabilities or otherwise binds the non-enforcing Party or that involves an admission of the invalidity or unenforceability of the Licensed IP or any other of the non-enforcing Party’s
intellectual property or that could reasonably be likely to restrict the non-enforcing Party from conducting its business, may be entered into without the express written consent of such non-enforcing Party, which consent shall not be unreasonably
withheld. 
  

 17 

 (d) Development and Supply Agreement Patents. To the extent that Section 5.2 of
the Development and Supply Agreement provides for different terms and conditions with respect to the prosecution, maintenance and enforcement of certain Licensed Patents Created By Luna under the Development and Supply Agreement, such terms and
conditions in the Development and Supply Agreement shall take precedence (and, to the extent inconsistent, apply in lieu of this Article 5) with respect to such Licensed IP. Without limiting the foregoing, enforcement of any Licensed Patents Created
By Luna under the Development and Supply Agreement within the Medical Robotics Field shall be enforced under Section 5.2(b) above as if such section also included the Medical Robotics Field solely with respect to such Licensed Patents.

 (e) Certain Indemnities. In the event a Party brings an enforcement action with respect to the Licensed IP under this
Section 5.2 (the “Indemnifying Party”), such Indemnifying Party shall indemnify the other Party (the “Indemnitee”) for any damages, awards, costs and out-of-pocket expenses imposed on or incurred by the
Indemnitee as a result of (and to the extent arising from the subject matter of) such enforcement action (including such damages, awards, costs and expenses resulting from such Indemnitee being named as a party to such action or resulting from any
court order for costs, fees, penalties, and other amounts (including the posting of bonds, if any) that may be imposed against the Indemnitee in such enforcement proceedings, to the extent such court order does not arise from such Indemnitee’s
own actions (unless such actions were directed to be taken by the Indemnifying Party)). Notwithstanding any of the foregoing to the contrary, such indemnification by the Indemnifying Party shall exclude any damages, awards, costs or expenses to the
extent based on claims (including cross-claims or counterclaims) that are brought against the Indemnitee with respect to subject matter outside of the infringement, misappropriation, validity or enforceability of the Licensed IP asserted in the
action (and outside the actions or omissions of the Indemnifying Party in conducting such enforcement action) or with respect to subject matter which concerns actions or omissions of the Indemnitee that were not directed to be taken or omitted by
the Indemnifying Party, in each case, so long as the Indemnitee has the sole right to control the actions based on such claims or subject matter. 
 6. MISCELLANEOUS 
 6.1 Entire Agreement. Subject to Section 6.7
below and the Amended Plan and Confirmation Order, this Agreement (and its Exhibits) contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes and merges all prior and contemporaneous
understandings and agreements between the parties, whether written or oral, with respect to such subject matter, it being understood and agreed that (i) the Hansen-Luna Agreement is being amended and restated in its entirety in this Agreement
(but not terminated or superseded) and (ii) the NDA survives in accordance with its terms for the purpose of disclosures made under the NDA prior to the effective date of the Hansen-Luna Agreement (provided, however, that, for the avoidance of
doubt and notwithstanding anything in the NDA to the contrary, any information disclosed under the NDA which falls within the Licensed IP may be used and disclosed by Hansen in accordance with the terms and conditions of the licenses granted
hereunder and the confidentiality provisions in the Development and Supply Agreement, and the NDA shall not restrict such permitted use and disclosure). This Agreement shall not be modified, amended or cancelled other than in a writing signed by
authorized representatives of Luna and Hansen. 
  

 18 

 6.2 No Implied Waiver. Any waiver of any obligation under this Agreement must be in
writing. The failure of any Party to enforce at any time any provision of or right under this Agreement shall not be construed to be a waiver of such provision or right or any other provision, and shall not affect the right of such Party to enforce
such provision or right or any other provision. No waiver of any breach hereof shall be construed to be a waiver of any other breach. 
 6.3 Assignment. This Agreement and the rights of the Parties hereunder may not be assigned by a Party without the prior written consent of the other Party; provided, however, this Agreement (along with the rights granted under this
Agreement) may be assigned by a Party without the other Party’s consent to an Affiliate or as part of (i) a merger, consolidation, internal reorganization, or acquisition of the assigning Party or (ii) a sale of all or substantially
all the assets of the assigning Party. In the event that Luna is acquired by a third party (such third party, hereinafter referred to as an “Acquiror”), then the intellectual property of such Acquiror held or developed by such
Acquiror (whether prior to or after such acquisition) shall, notwithstanding anything else in this Agreement to the contrary, be excluded from the Licensed IP, and such Acquiror (and Affiliates of such Acquiror which are not Subsidiaries of Luna
itself) shall be excluded from the meaning of “Affiliate” solely for purposes of the applicable components of the foregoing intellectual property definitions, in all such cases if and only if: (a) Luna remains a Subsidiary of the
Acquiror; (b) substantially all intellectual property of Luna and substantially all research and development assets and operations of Luna, in each case relating to FOSSL Technology, remain with Luna and are not transferred to the Acquiror or
another Affiliate of the Acquiror; and (c) the scientific and development activities with respect to FOSSL Technology of Luna and the Acquiror (if any) are maintained separate and distinct. For clarity, in the event that Luna is acquired by an
Acquiror and each of the criteria described in subclauses (a) through (c) is not satisfied, then the intellectual property of such Acquiror created, invented, generated or developed after the date of such acquisition shall be included
within Licensed IP (but not any intellectual property of such Acquiror existing prior to or as of the date of such acquisition). Subject to the foregoing, the respective obligations of the Parties hereto shall bind, and the respective rights
of the Parties shall inure to the benefit of, the Parties’ respective permitted assignees and successors. For the avoidance of doubt, any sale or transfer of Licensed IP or Hansen Licensed IP shall only be made fully subject to the terms and
conditions of this Agreement. 
 6.4 Governing Law; Jurisdiction; Venue. 
 (a) Choice of Law. This Agreement shall be governed by, and interpreted in accordance with: (i) the Bankruptcy Code, and
(ii) in the case of applicable non-bankruptcy law, the laws of the State of Delaware, without regard to conflicts of laws, or applicable federal law as to a particular subject where federal law governs, such as for example, the Patent Act
governing patents or the Copyright Act governing copyrights. 
 (b) Bankruptcy Court Jurisdiction. Except as provided in
subsection (c) and subsection (d), any disputes arising under this Agreement, or related to the meaning, effect and interpretation of the Amended Plan, the Confirmation Order or this Agreement (which Agreement is a part of the Amended Plan and
Confirmation Order), shall be subject to the jurisdiction of the Bankruptcy Court. 
 (c) Exceptions to Bankruptcy Court
Jurisdiction. In the event: (i) the Bankruptcy Court lacks or declines to exercise jurisdiction over a dispute arising under this Agreement, for any reason; (ii) the reference of jurisdiction to the Bankruptcy Court is withdrawn, for
any reason; (iii) the dispute or enforcement of this Agreement is related to any intellectual property rights of Intuitive, Hansen or Luna, including without limitation any alleged infringement or misappropriation or misuse thereof; or
(iv) the dispute or enforcement arises from or with respect to any provision of, or incorporated into, any of Sections 2.1, 2.2, 2.3, 2.4, 2.5, 4, 5, or 6.3 of this Agreement or causes of action relating

  

 19 

 
thereto or arising therefrom, or any of Sections 2.1, 2.2, 3, 4, 5, 7, 8 or 10.3 of the Development and Supply Agreement or causes of action relating thereto or arising therefrom, then the state
or federal courts for or in New Castle County, Delaware shall have exclusive jurisdiction over any disputes arising under or related to this Agreement. 
 (d) Alternative Dispute Resolution. Notwithstanding subsections (b) and (c) above and subsection (e) below, in the event some provision of a particular Hansen Settlement Document
expressly creates an alternative dispute resolution provision as to a particular type of dispute, then such disputes shall be resolved as so specified in the applicable Agreement. 
 (e) Consent to Jurisdiction. Each Party hereby (i) consents and submits to the venue and co-exclusive jurisdiction of the
Bankruptcy Court and the courts of New Castle County in the State of Delaware and the Federal courts of the United States sitting in such part of the District of Delaware (without prejudice to either the retained rights and jurisdiction of the
Bankruptcy Court), (ii) agrees that all claims may be heard and determined in such courts, (iii) irrevocably waives (to the extent permitted by applicable law) any objection that it now or hereafter may have to the laying of venue of any
such action or proceeding brought in any of the foregoing courts, and any objection on the ground that any such action or proceeding in any such court has been brought in an inconvenient forum, and (iv) agrees that a final judgment in any such
action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner permitted by law. Each of the Parties hereby consents to service of process by any party in any suit, action or
proceeding in accordance with such applicable law. 
 (f) Resolving Conflicts. If there is any question as to whether
the proper jurisdiction or venue for any dispute is in the Bankruptcy Court or in the Delaware Court, the Bankruptcy Court may decide that issue. 
 (g) Miscellaneous. The prevailing Party in any final judgment of any such controversy, claim or dispute, or the non-dismissing Party in the event of a dismissal without prejudice, shall be entitled
to receive from the other Party the reasonable attorneys’ fees (and all related costs and expenses) and all other costs and expenses paid or incurred by such prevailing Party in connection with such controversy, claim or dispute and in
connection with enforcing any judgment or order with respect thereto. 
 6.5 Severability. If for any reason a provision
of this Agreement, or portion thereof, is finally determined to be unenforceable under applicable law, that provision, or portion thereof, shall nonetheless be enforced, as to circumstances, persons, places and otherwise, to the maximum extent
permissible by applicable law so as to give effect to the intent of the parties, and the remainder of this Agreement shall continue in full force and effect. 
 6.6 Effect of Plan/Confirmation Order. The Parties agree that this Section 6.6 is a settlement proposal that shall apply only to the extent approved by the Confirmation Order. The Parties each
agree to use commercially reasonable efforts to support the full rights sought by the Parties hereunder, including without limitation by appropriate proffers or other proof in the plan confirmation process. To the maximum extent possible under
applicable law (as affected by the Confirmation Order), this Agreement is not an “executory contract” for the purposes of 11 U.S.C. § 365. Rather, this Agreement constitutes a settlement allocation and partition of intellectual
property and other rights disputed in the Litigation and in Hansen’s related claims in the Chapter 11 Case but resolved by the Amended Plan and the Confirmation Order. To the extent that a final judgment by a court of competent jurisdiction
rules otherwise than that, the executory parts of this Agreement (herein sometimes called a

  

 20 

 
“Section 365(n) Contract”) shall be interpreted so that the greatest possible rights and licenses of the licensee Party thereto shall be held to be “executed,” thereby
minimizing any “executory” parts of the Agreement. As to any Section 365(n) Contract, the parties hereto acknowledge and agree that the rights and licenses granted by the licensor Party to the licensee Party and its Affiliates
hereunder are rights with respect to intellectual property (including without limitation “intellectual property” within the meaning of 11 U.S.C. § 101), and: (a) all reports, drawings, samples, prototypes and other books and
records and embodiments of the intellectual property shall be deemed “embodiments” of the intellectual property protected by 11 U.S.C. § 365 hereunder; (b) any Hansen Settlement Document or obligations thereunder that the
licensee Party designates as such an “agreement supplementary” to such Section 365(n) Contract in its discretion at any time before the Confirmation Hearing in a “Plan Supplement” to the Amended Plan, shall be, to the extent
permitted by applicable law (as affected by the Confirmation Order) and so designated by the licensee, an “agreement supplementary” to such Section 365(n) Contract, but no other Hansen Settlement Document or obligations shall be an
“agreement supplementary” to such Section 365(n) Contract; and (c) there are no “royalty payments” due from Hansen or Luna as a licensee under such Section 365(n) Contract or, since 11 U.S.C. § 365(n)(2)
applies only to the Section 365(n) Contract, but not to any “agreement supplementary” to such contract, under any such supplementary agreement. In the event of any conflict between (i) the provisions of this Section 6.6, or
(ii) the rights contemplated by 11 U.S.C. § 365(n), and the Amended Plan or the Confirmation Order, the Amended Plan and Confirmation Order shall govern and control. Hansen and Luna each shall be deemed to have made a request for
enforcement of all of its rights and licenses pursuant to 11 U.S.C. § 365(n)(4), without further action by either licensee Party. 
 6.7 Confidentiality. Confidential information within the Licensed IP and Hansen Licensed IP shall be subject to the terms and conditions of the confidentiality provisions set forth in the Development and Supply Agreement. 

6.8 Headings. The headings and captions used in this Agreement are for convenience only and shall not be considered in construing
or interpreting this Agreement. 
 6.9 Interpretation. This Agreement has been negotiated by all parties, and each Party
has been advised by competent legal counsel. This Agreement shall be interpreted in accordance with its terms and without any construction in favor of or against any Party. 
 6.10 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but which collectively
shall constitute one and the same instrument. 
 6.11 No Effect on 2005 Hansen-Intuitive Cross License. The 2005
Hansen-Intuitive Cross License shall remain in full force and effect and the terms of such 2005 Hansen-Intuitive Cross License shall in no way be modified, affected or superseded by this Agreement. 
 6.12 Notices. Except as may be otherwise provided herein, all notices, requests, waivers, consents and approvals made pursuant to
this Agreement shall be in writing and shall be conclusively deemed to have been duly given (a) when hand delivered to another Party; (b) when sent by facsimile, with receipt confirmation, to the number set forth below if sent between 8:00
a.m. and 5:00 p.m. recipient’s local time on a business day, or on the next business day if sent by facsimile to the number set forth below if sent other than between 8:00 a.m. and 5:00 p.m. recipient’s local time on a business day;
or (c) the next business day after deposit with a national overnight delivery service, postage prepaid, addressed to the applicable Parties as set forth below with next business day delivery guaranteed, provided that the sending Party receives
a confirmation of delivery from the delivery service provider. Each person making a communication hereunder by facsimile shall attempt to promptly confirm by

  

 21 

 
telephone to the person to whom such communication was addressed each communication made by it by facsimile pursuant hereto but the absence of such confirmation shall not affect the validity or
delivery status of any such communication. A Party may change or supplement the addresses given below, or designate additional addresses, for purposes of this Section by giving the other Parties written notice of the new address in the manner set
forth above. 
 If to Hansen Medical, Inc. 
   800 E. Middlefield Road 
   Mountain View, CA 94043

   Attn: Arthur Hsieh 
   Facsimile: 650-404-5901 
   Email:
Arthur_Hsieh@hansenmedical.com 
 If to Luna Innovations Inc. or Luna Technologies, Inc. 
   One Riverside Circle, Suite 400 
   Roanoke, VA 24016 
   Attn: 
   Facsimile: 
 6.13 Luna Party. For purposes of this Agreement, Luna Innovations Inc. and Luna Technologies, Inc. may be treated by Hansen as one entity, such that, for example, a notice or consent from Luna Innovations Inc. shall be deemed a valid
and effective notice or consent also from Luna Technologies, Inc. (and vice versa) and a payment from Hansen to Luna Innovations Inc. shall fully satisfy Hansen’s obligation with respect to such payment hereunder as to both entities. Luna
Innovations Inc. and Luna Technologies, Inc. shall exercise their rights jointly under this Agreement, and will not take conflicting positions with respect to its obligations to Hansen. 
 6.14 Further Assurances. Each Party agrees to take or cause to be taken such further actions, and to execute, deliver and file or
cause to be executed, delivered and filed such further documents and instruments, and to obtain such consents, as may be reasonably required or requested by the other Party (to the extent consistent with this Agreement and at the other Party’s
expense) in order to effectuate fully the purposes, terms and conditions of this Agreement. Without limiting the foregoing, each Party shall take such steps reasonably requested by the other Party to perfect, and provide constructive notice of, the
licenses and other rights granted to such Party hereunder, including without limitation filings in any governmental office where that is customary or appropriate in accordance with applicable law. 
 [Signature Page Follows] 
  

 22 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized
representatives as of the Effective Date. 
  

									
	LUNA INNOVATIONS INCORPORATED	 		 	HANSEN MEDICAL, INC.
					
	By:	 	  
	 		 	By:	 	  

					
	Name:	 	  
	 		 	Name:	 	  

					
	Title:	 	  
	 		 	Title:	 	  

				
	LUNA TECHNOLOGIES, INC.	 		 		 	
					
	By:	 	  
	 		 		 	
					
	Name:	 	  
	 		 		 	
					
	Title:	 	  
	 		 		 	

 EXHIBIT A 
 Hansen-Luna Agreement IP 
 [****] 
 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS 

 EXHIBIT B 
 Listed Patents and Patent Applications within Licensed Patents 
 [****] 
 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 

 EXHIBIT C 
 Certain Luna Technology within Licensed Technology 
 [****] 
 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 

 EXHIBIT D 
 Third Party Licenses 
 [****] 
 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS 

 EXHIBIT E 
 Hansen Patents 
 [****] 
 [****] = CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]